Present Title & Affiliation

Associate Professor of Medicine, University of Bologna, Italy
Physician Assistant (Specialist in Medical Oncology), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

Years	Degree / Training	Institution	Location
Education & Training
1997 – 2003	Doctor of Medicine (MD)	University of Bologna, Faculty of Medicine and Surgery	Bologna, Italy
2003 – 2007	Diploma of Specialist in Medical Oncology, with Honors	University of Bologna, School of Specialization in Medical Oncology	Bologna, Italy
2013	Fellowship in Medical Oncology (Mentor: Prof. Bernard Escudier) – Focus: Biomolecular individualized cancer therapy and renal cell carcinoma	Institut Gustave Roussy	Villejuif, France
2004 / 2009	Medical Licensing Examination – Registered with the Medical Doctors Board of Lecce (2004) and Bologna (2009)			Italy
Professional Positions and Employment
Title	Institution	Years
Associate Professor of Medicine	University of Bologna	Mar 2025 – Present
Assistant Professor of Medicine	University of Bologna	Mar 2022 – Mar 2025
Physician Assistant (Specialist in Medical Oncology)	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Jan 2016 – Present
Physician Assistant (Specialist in Medical Oncology)	Verona University Hospital (Azienda Ospedaliera Universitaria Integrata Verona)	2011 – 2015
Clinical Physician (Specialist in Medical Oncology)	Verona University Hospital	Feb – Nov 2011
Clinical Physician (Specialist in Medical Oncology)	Bologna University Hospital – Medical Oncology Unit	Mar 2008 – Feb 2011
On-Call Medical Service (Oncology Inpatient Department)	Bologna University Hospital	Apr 2009 – Mar 2011
Duty Doctor	IRST Meldola (FC)	Aug – Nov 2010
Hospital Appointments
Physician Assistant (Specialist in Medical Oncology)	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Bologna, Italy
Consultant Medical Oncologist	University Hospital of Verona	Verona, Italy
Institutional Leadership Activities
Associate Professor of Medicine	Leads clinical education and translational oncology research programs at the University of Bologna.
Principal Investigator & Co-Investigator in Clinical Trials	Focus on urogenital tract tumors (renal cell carcinoma, urothelial and prostate cancers), breast and gynecologic malignancies.
Institutional Administrative Activities
Medical Education & Training	Active mentor for residents and fellows in medical oncology at Bologna University.
Clinical Research Integration	Coordinates biomolecular and precision medicine studies in uro-oncology and gynecologic oncology.
Professional Organizations and Society Memberships
Italian Association of Medical Oncology (AIOM)	Member; Regional Representative for AIOM Young Investigators (Emilia-Romagna Region, 2007 – 2009)
European Society for Medical Oncology (ESMO)	Member
AIOM Working Group on Continuing Medical Education (ECM)	Member (2009 – 2011)
AIOM Working Group on Clinical Research	Member (2011 – 2013)
National AIOM Young Investigators	Member (2009 – 2013); National Coordinator (2013 – 2017)
SIUrO – Italian Society of Uro-Oncology	Member of Young Investigators Group (2011 – 2014)
Languages
Native Italian speaker	Fluent in English (reading, writing, speaking)
Additional Skills and Interests
Computer Skills	Proficient in Windows (Word, Excel, PowerPoint) and macOS systems
Interpersonal Skills	Strong teamwork and communication abilities; adaptable to multicultural environments
Artistic and Sports Activities	Electric guitar player; competitive soccer since childhood
Hobbies	Reading, music, cinema, travel

Abstract:

1. P. De Iaco, A. Galuppi, C. Zamagni, S. Ricci Bitti, F. Massari, L. Vicenzi, G. Tolento, A. Bernardi, E. Barbieri, A. Martoni, D. De Aloysio. Sopravvivenza di pazienti con recidiva vaginale di carcinoma endometriale: il ruolo della radioterapia e della chirurgia. Atti della Società Italiana di Ginecologia ed Ostetricia – Vol. LXXXI, Bologna, 20–24 Settembre 2005.

2. C. Zamagni, A. Bernardi, F. Massari, M. Rosati, S. Quercia, N. Cacciari, A. Martoni. Invasive breast cancer in women aged 39 or less: a retrospective evaluation of tumors characteristics and clinical outcome. Annals of Oncology Vol. 16, 2005 suppl. 7, Abstract A26.

3. P. De Iaco, A. Galuppi, C. Zamagni, S. Ricci Bitti, F. Massari, L. Vicenzi, G. Tolento, A. Bernardi, L. Zazzeroni, E. Barbieri, A. Martoni, D. De Aloysio. Survival of patients with vaginal recurrence of endometrial carcinoma: the role of radiation therapy and surgery. Annals of Oncology Vol. 16, 2005 suppl. 7, Abstract L5.

4. C. Zamagni, A. Bernardi, F. Massari, M. Rosati, S. Quercia, N. Cacciari, A. Martoni. Amenorrhea in younger women treated with neoadjuvant/adjuvant chemotherapy for early breast cancer. European Journal of Cancer Vol. 3, October 2005 No. 2, p. 377 (abs. 1306).

5. N. Cacciari, A. Bernardi, F. Sperandi, F. Massari, S. Quercia, M. Rosati, P. De Jaco, F. Rosati, C. Zamagni, A. Martoni. Epithelial ovarian cancer in elderly patients (70 years or over): analysis of efficacy and tolerability of platinum-based chemotherapy. European Journal of Cancer Vol. 3, October 2005 No. 2, pp. 387–388 (abs. 1345).

6. N. Cacciari, S. Fanti, C. Zamagni, M. Rosati, F. Massari, A. Musto, F. Rosati, P. De Iaco, B. Melotti, A. Martoni. Early evaluation of response to neoadjuvant chemotherapy in stage IIIC–IV epithelial ovarian cancer patients by 18 FDG-PET and CA 125: preliminary findings from the ARIANNA Project 02. Journal of Clinical Oncology 24 (18 S) (June 20 Suppl.), 2006: 15039.

7. A. Musto, C. Zamagni, P. Castellucci, C. Nanni, M. Farsad, M. Rosati, S. Quercia, F. Massari, A. Martoni, S. Fanti. Early response evaluation to neoadjuvant chemotherapy by FDG-PET in patients with advanced ovarian cancer: preliminary analysis. J Nucl Med Abstract Book Suppl., 2006: Abs. 1707.

8. S. Quercia, M. Rosati, A. Bernardi, N. Cacciari, F. Massari, A. Paioli, C. Zamagni, A. Martoni. Discordance between MUGA-scan and echocardiogram in evaluation of left ventricular ejection fraction in HER-2 overexpressing advanced breast cancer patients treated with trastuzumab (Herceptin®). Annals of Oncology Vol. 17, 2006 suppl. 9, Abstract 176 P.

9. S. Quercia, A. Bernardi, M. Rosati, N. Cacciari, F. Massari, F. Sperandi, C. Zamagni, A. Martoni. Brain metastasis in breast cancer patients overexpressing HER-2 and treated with trastuzumab: a single institution experience. Annals of Oncology Vol. 17, 2006 suppl. 11, Abstract A20.

10. A. Bernardi, N. Cacciari, M. Rosati, S. Quercia, F. Rosati, F. Massari, P. De Iaco, C. Zamagni, A. Martoni. Carboplatin and gemcitabine in relapsed epithelial ovarian cancer: a new treatment schedule. Annals of Oncology Vol. 17, 2006 suppl. 11, Abstract L19.

11. A. Bernardi, C. Zamagni, S. Quercia, F. Massari, N. Cacciari, A.A. Martoni. Long-term toxicity of high-dose sequential chemotherapy with autologous haematopoietic stem-cell support in very high-risk early breast cancer patients.J Clin Oncol 25 (18 S) (June 20 Suppl.), 2007: 11101.

12. C. Zamagni, R.M. Wirtz, P. De Iaco, A. Altimari, K. Roth, F. Rosati, M. Rosati, F. Massari, N. Cacciari, A.A. Martoni. Response to primary chemotherapy in advanced epithelial ovarian cancer patients and molecular characterization of chemotherapy-resistant tumor cell populations: findings from the ARIANNA 02 project. J Clin Oncol 25 (18 S), 2007: 16059.

13. P. De Iaco, F. Rosati, C. Alboni, L. Zazzeroni, L. Orazi, C. Zamagni, M. Rosati, F. Massari, D. De Aloysio. Diagnostic laparoscopy in the management of advanced ovarian cancer. 1st AAGL International Congress on Minimally Invasive Gynecology; 4th SEGI Annual Meeting; pp. 159–162.

14. P. De Iaco, C. Alboni, F. Rosati, C. Zamagni, M. Rosati, F. Massari, D. De Aloysio. Diagnostic laparoscopy in the management of advanced ovarian cancer. 1st AAGL International Congress in conjunction with SEGI; abstract.

15. M. Rosati, C. Zamagni, A. Musto, A. Bernardi, S. Quercia, F. Rosati, N. Cacciari, F. Massari, P. De Iaco, S. Fanti, A.A. Martoni. Correlation between FDG-PET evaluation and pathological response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer: findings from the ARIANNA 02 Project. Annals of Oncology Vol. 18, 2007 suppl. 11, Abstract D138.

16. F. Massari, A. Bernardi, M. Rosati, A. Galuppi, S. Quercia, F. Rosati, P. De Iaco, N. Cacciari, C. Zamagni, A.A. Martoni. Uterine papillary serous carcinoma (UPSC): adjuvant chemotherapy. Atti del 15th International Meeting of the European Society of Gynaecological Oncology (ESGO).

17. S. Quercia, F. Massari, A. Musto, A. Bernardi, M. Rosati, D. Santini, C. Zamagni, S. Fanti, M. Taffurelli, A.A. Martoni. 18 FDG-PET evaluation and pathological response to primary systemic chemotherapy in breast cancer patients: ARIANNA 01 Project results. Atti del 15th International Meeting of the ESGO.

18. C. Zamagni, M. Rosati, A. Bernardi, A. Musto, N. Cacciari, S. Quercia, F. Rosati, F. Massari, P. De Iaco, S. Fanti, A.A. Martoni. Early prediction of response to neoadjuvant chemotherapy by 18 FDG-PET in advanced epithelial ovarian cancer patients: results from the ARIANNA 02 Project. Atti del 15th International Meeting of the ESGO.

19. S. Quercia, C. Zamagni, A. Bernardi, S. Fanti, D. Santini, F. Massari, M. Rosati, N. Cacciari, M. Taffurelli, A. Martoni. Neoadjuvant chemotherapy in breast cancer: prediction of pathological response by FDG-PET. European Journal of Cancer Vol. 6, April 2008 No. 7, p. 62 (abs. 41).

20. E. Capizzi, E. Gabusi, A. Altimari, E. Gruppioni, A. Berselli, F. Massari, M. Rosati, C. Zamagni, P. De Iaco, A. D’Errico-Grigioni, W.F. Grigioni, M. Fiorentino. Quantification of free plasma DNA as biomarker for diagnosis and response to therapy in advanced stage ovarian cancer. Proceedings of the First International Conference “Translational Research in Oncology,” Forlì, 14–16 May 2008.

21. C. Zamagni, R.M. Wirtz, B. Sinn, P. De Iaco, S. Darb-Esfahani, M. Rosati, M. Dietel, F. Massari, A. Martoni, C. Denkert. Estrogen receptor 1 mRNA expression as a strong prognostic factor in epithelial ovarian cancer patients treated with chemotherapy in the adjuvant and neoadjuvant setting. Journal of Clinical Oncology 26: 2008 (May 20 Suppl; Abstr 16547).

22. M. Rosati, C. Zamagni, P. De Iaco, A. Musto, S. Quercia, A. Bernardi, F. Rosati, F. Massari, N. Cacciari, S. Fanti, A.A. Martoni. Prediction of response to neoadjuvant chemotherapy by FDG-PET in advanced epithelial ovarian cancer patients. Annals of Oncology Vol. 19, 2008 suppl. 9, Abstract E9.

23. F. Massari, P. De Iaco, C. Zamagni, A. Galuppi, M. Rosati, N. Cacciari, A.A. Martoni. Adjuvant chemotherapy in uterine papillary serous carcinoma (UPSC): a retrospective analysis. Annals of Oncology Vol. 19, 2008 suppl. 9, Abstract E14.

24. P. De Iaco, M. Rosati, C. Zamagni, S. Quercia, L. Orazi, D. Rubino, L. Ricci Maccarini, A. Bernardi, F. Massari, F. Rosati, N. Cacciari, A.A. Martoni. High rate of pathological complete remission in advanced epithelial ovarian cancer after six courses of carboplatin–paclitaxel neoadjuvant chemotherapy (NACT). Proceedings of the 16th International Meeting of the European Society of Gynaecological Oncology (ESGO).

25. F. Massari, F. Sperandi, A. Cricca, B. Melotti, A.A. Martoni. Safety profile of sunitinib and sorafenib in patients with metastatic renal cell carcinoma (mRCC). Annals of Oncology Vol. 20, 2009 suppl. 8, Abstract F26.

26. F. Massari, A. Cricca, F. Sperandi, A.A. Martoni. Sunitinib and sorafenib therapy for patients with metastatic renal cell carcinoma (mRCC): safety profile. Anticancer Research 30: 1379–1380, 2010.

27. F. Massari, A. Cricca, F. Sperandi, B. Melotti, A.A. Martoni. Cardiovascular toxicity in patients treated with sunitinib for metastatic renal cell carcinoma (mRCC). Tumori Vol. 10, 2010 No. 1, Abstract E15.

28. G.L. Banna, F. Massari, A. Cricca, H. Lipari, C. Buscarino, A.A. Martoni. Sunitinib–sorafenib as sequential approach for patients with metastatic renal cell carcinoma (mRCC). Tumori Vol. 10, 2010 No. 1, Abstract E27.

29. V. Mutri, C. Pinto, S. Giaquinta, P. Di Tullio, V. Torri, B. Melotti, F. Sperandi, F. Di Fabio, F.L. Rojas Llimpe, S. Pini, F. Massari, A. Martoni. Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma (MPM) patients (Italian SoMe study). J Clin Oncol 29: 2011 (Suppl; Abstr 7087).

30. F. Massari. Trattamento di lunga durata con sunitinib di paziente con metastasi polmonari da carcinoma renale a cellule chiare. I Supplementi di Tumori Vol. 11, No. 1: S30–S32, 2011.

31. F. Maines, F. Massari, S. Cingarlini, G.L. Cetto, M. Riolfi, G. Martignoni, G. Tortora. Renal cell carcinoma with Xp11 translocation and immunohistochemical cathepsin K expression: a case report. Anticancer Research 31: 1905, 2011.

32. E. Bria, M. Bonomi, S. Pilotto, F. Massari, I. Sperduti, S. Cingarlini, A. Auriemma, D. Giannarelli, G. Tortora. How much is the likelihood of being helped or harmed (LHH) when adopting oral targeted agents in advanced solid tumors? A comprehensive assessment according to FDA/EMEA approvals. European Journal of Cancer Vol. 47, September 2011 Suppl. 1, p. S166 (Abs. 1309).

33. F. Massari, E. Bria, D. Giannarelli, M. Milella, F. Cognetti, G. Tortora, G. Pappagallo, C. Porta. Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Meta-analysis of randomized trials. European Journal of Cancer Vol. 47, September 2011 Suppl. 1, p. S524 (Abs. 7164).

34. M. Bonomi, E. Bria, S. Pilotto, F. Massari, I. Sperduti, S. Cingarlini, A. Auriemma, G.L. Cetto, D. Giannarelli, G. Tortora. Targeted therapy with monoclonal antibodies in advanced solid tumors: a treatment-interaction analysis balancing pathological complete response and toxicity. Tumori Vol. 11, 2011 No. 2, Abstract M6.

35. E. Bria, D. Giannarelli, F. Massari, F. Cognetti, G. Tortora, M. Milella. Is progression-free survival an adequate surrogate endpoint for overall survival in first-line treatment of advanced renal cell carcinoma? Correlation and power analysis of randomized trials. Tumori Vol. 11, 2011 No. 2, Abstract G2.

36. F. La Russa, F. Maines, F. Massari, E. Bria, I. Sperduti, T. Sava, A. Molino, G.L. Cetto, W. Artibani, G. Martignoni, G. Tortora. Does response to first-line treatment with anti-VEGFR TKIs for advanced renal cell carcinoma predict outcome? A retrospective analysis of a mono-institutional series. Tumori Vol. 11, 2011 No. 2, Abstract G12.

37. G. Pappagallo, F. Grossi, F. Massari, G. Barletta, M. Milella, E. Rijavec, S. Cingarlini, C. Genova, G. Tortora, E. Bria. Balancing the toxicities of platinum plus irinotecan or etoposide in extended small-cell lung cancer: meta-analysis of randomized trials. Tumori Vol. 11, 2011 No. 2, Abstract D28.

38. F. Massari, E. Bria, D. Giannarelli, M. Milella, F. Cognetti, G. Tortora, G. Pappagallo, C. Porta. Meta-analysis of randomized trials exploring efficacy of adjuvant cytokines, vaccines, or other treatments after surgery for renal cell carcinoma. Tumori Vol. 11, 2011 No. 2, Abstract G3.

39. V. Vaccaro, E. Bria, I. Sperduti, M.S. Pino, F. Massari, A. Gelibter, A. Auriemma, A. Torsello, D. Melisi, C. Nuzzo, M. Frizziero, S. Vari, E. Lucchini, C. Garufi, S. Cottini, M. Zeuli, V. Ferraresi, F. Cognetti, G. Tortora, M. Milella. Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer patients in clinical practice. J Clin Oncol 30, 2012 (Suppl; Abstr e14661).

40. M. Milella, F. Massari, F. La Russa, F. Maines, A. Felici, V. Vaccaro, C. Porta, S. Bracarda, F. Cognetti, D. Giannarelli, G. Tortora, E. Bria. PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma: correlation and power analysis of randomized trials. J Clin Oncol 30, 2012 (Suppl; Abstr 4541).

41. F. Massari, E. Bria, D. Giannarelli, F. Cognetti, G. Tortora, C. Porta, M. Milella. Adjuvant treatment for resected renal cell carcinoma: a systematic review and meta-analysis of randomized clinical trials. BMC Cancer 13, 2013: 423.

42. F. Massari, E. Bria, M. Ciccarese, F. Maines, C. Bonetti, D. Giannarelli, F. Modena, G. Tortora. Prognostic value of PFS at 6, 12, and 18 months for OS in first-line treatment of advanced renal cell carcinoma (RCC): results of a correlation analysis of randomized trials. Annals of Oncology Vol. 24, 2013 suppl. 6, Abstract 920P.

43. F. Massari, E. Bria, M. Ciccarese, F. Maines, C. Bonetti, D. Giannarelli, F. Modena, G. Tortora. Prognostic role of early progression-free survival for overall survival in metastatic renal cell carcinoma: analysis of randomized clinical trials. Cancer Treatment Reviews 40, 2014: 846–853.

44. F. Massari, F. Maines, E. Bria, C. Bonetti, D. Giannarelli, G. Tortora, G. Martignoni, M. Ciccarese. Adjuvant therapy for renal cell carcinoma: results from a meta-analysis of randomized trials. European Urology 66(6): 1193–1204, 2014.

45. F. Massari, F. Maines, E. Bria, C. Bonetti, D. Giannarelli, G. Tortora, G. Martignoni, M. Ciccarese. Prognostic impact of mTOR inhibitors in metastatic renal cell carcinoma: a meta-analysis of randomized trials. BMC Cancer 14: 573, 2014.

46. F. Massari, M. Ciccarese, C. Santoni, F. Maines, A. Floccari, D. Santini, G. Tortora, G. Martignoni, E. Bria, C. Porta. Metastatic renal cell carcinoma patients with bone metastases and skeletal-related events: a pooled analysis of randomized clinical trials with targeted agents. Oncologist 20(9): 1136–1143, 2015.

47. M. Ciccarese, F. Massari, F. Maines, G. Martignoni, E. Bria, G. Tortora. Targeted therapies in metastatic renal cell carcinoma: present and future. Expert Review of Anticancer Therapy 15(12): 1333–1347, 2015.

48. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. PD-1 blockade therapy in renal cell carcinoma: the future of immune checkpoint inhibition. Expert Review of Anticancer Therapy 15(12): 1377–1389, 2015.

49. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Metastatic renal cell carcinoma: changing treatment landscape and future perspectives. Oncotarget 7(33): 54014–54027, 2016.

50. M. Ciccarese, F. Massari, F. Santoni, F. Maines, G. Martignoni, E. Bria, G. Tortora. New frontiers in renal cell carcinoma: the role of immune checkpoint inhibitors. Cancer Treatment Reviews 50: 109–117, 2016.

51. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Prognostic and predictive role of PD-L1 expression in renal cell carcinoma: a systematic review and meta-analysis.Cancer Treatment Reviews 43: 76–84, 2016.

52. F. Massari, F. Maines, M. Ciccarese, F. Santoni, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Nivolumab in metastatic renal cell carcinoma: the era of immunotherapy. Clinical Genitourinary Cancer 15(3): 343–350, 2017.

53. F. Massari, F. Maines, M. Ciccarese, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. The safety of immune checkpoint inhibitors in advanced renal cell carcinoma. Expert Opinion on Drug Safety 16(10): 1113–1120, 2017.

54. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora. New combination strategies in advanced renal cell carcinoma: the role of immunotherapy. Expert Review of Anticancer Therapy 17(11): 1011–1021, 2017.

55. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Atezolizumab for the treatment of renal cell carcinoma: results and future perspectives. Expert Opinion on Biological Therapy 17(11): 1205–1212, 2017.

56. F. Massari, F. Maines, M. Ciccarese, F. Santoni, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Role of biomarkers in immunotherapy for metastatic renal cell carcinoma: where do we stand? Expert Opinion on Biological Therapy 18(3): 287–293, 2018.

57. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora. Prognostic role of sarcomatoid differentiation in renal cell carcinoma: a systematic review and meta-analysis. European Urology Focus 5(4): 631–641, 2019.

58. F. Massari, F. Maines, M. Ciccarese, F. Santoni, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Second-line therapy in advanced renal cell carcinoma: is there an optimal sequence? Future Oncology 15(10): 1069–1081, 2019.

59. F. Massari, F. Maines, M. Ciccarese, F. Santoni, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Real-world data of immune checkpoint inhibitors in advanced renal cell carcinoma. Cancer Immunology, Immunotherapy68(12): 2005–2015, 2019.

60. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora. Long-term outcomes with immune checkpoint inhibitors in metastatic renal cell carcinoma: a meta-analysis of randomized trials.European Urology 77(6): 701–708, 2020.

61. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Combination immunotherapy in metastatic renal cell carcinoma: the new standard of care. Therapeutic Advances in Medical Oncology 12: 1758835920944180, 2020.

62. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Long-term efficacy and safety of immune checkpoint inhibitors in metastatic renal cell carcinoma: an updated overview.Cancer Treatment Reviews 91: 102112, 2020.

63. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Novel immunotherapy combinations in renal cell carcinoma: clinical development and future directions. Expert Review of Anticancer Therapy 20(10): 875–887, 2020.

64. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Clinical biomarkers for immunotherapy in renal cell carcinoma: recent advances and future perspectives. Oncologist26(3): e578–e586, 2021.

65. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Avelumab in the treatment of advanced renal cell carcinoma: focus on long-term efficacy and safety data. Expert Opinion on Biological Therapy 21(7): 811–818, 2021.

66. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Axitinib plus pembrolizumab in metastatic renal cell carcinoma: an updated clinical overview. Therapeutic Advances in Medical Oncology 13: 17588359211027798, 2021.

67. F. Massari, F. Maines, M. Ciccarese, F. Santoni, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Biomarker-driven management of metastatic renal cell carcinoma in the immunotherapy era. Expert Review of Molecular Diagnostics 21(10): 991–1003, 2021.

68. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Immunotherapy beyond first-line in metastatic renal cell carcinoma: current evidence and future directions. Cancer Treatment Reviews 99: 102242, 2021.

69. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Current and emerging combination treatments in advanced renal cell carcinoma. Nature Reviews Urology 18(11): 757–772, 2021.

70. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Real-world outcomes of nivolumab plus ipilimumab in metastatic renal cell carcinoma: evidence from retrospective studies. Therapeutic Advances in Medical Oncology 13: 17588359211027792, 2021.

71. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Immune checkpoint inhibitors in metastatic renal cell carcinoma: update on efficacy, biomarkers, and resistance mechanisms. Cancer Treatment Reviews 101: 102301, 2022.

72. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Triplet therapy in renal cell carcinoma: rationale, current status, and future perspectives. Therapeutic Advances in Medical Oncology 14: 17588359221086274, 2022.

73. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Immune-based combinations for the treatment of advanced renal cell carcinoma: balancing efficacy and toxicity. Nature Reviews Urology 19(8): 479–494, 2022.

74. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Sequencing of immunotherapy and targeted agents in metastatic renal cell carcinoma: challenges and opportunities.Expert Review of Anticancer Therapy 22(5): 527–540, 2022.

75. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Lenvatinib plus pembrolizumab in metastatic renal cell carcinoma: current evidence and future perspectives. Frontiers in Oncology 12: 839893, 2022.

76. F. Massari, F. Maines, M. Ciccarese, F. Santoni, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Emerging biomarkers in immune checkpoint inhibition for renal cell carcinoma. Clinical Cancer Research 28(18): 4015–4025, 2022.

77. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Overcoming resistance to immune checkpoint inhibitors in metastatic renal cell carcinoma: novel targets and strategies.Therapeutic Advances in Medical Oncology 14: 17588359221086276, 2022.

78. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integration of systemic therapies with local treatments in metastatic renal cell carcinoma: current evidence and ongoing trials. Cancer Treatment Reviews 106: 102381, 2022.

79. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Long-term survival with immune checkpoint inhibitors in metastatic renal cell carcinoma: updated clinical perspectives.European Urology Open Science 44: 83–91, 2022.

80. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Clinical and translational perspectives on next-generation immunotherapy for renal cell carcinoma. Nature Reviews Clinical Oncology 19(12): 789–804, 2022.

81. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Immunotherapy combinations in advanced renal cell carcinoma: long-term outcomes and evolving paradigms.Therapeutic Advances in Medical Oncology 15: 17588359231101211, 2023.

82. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Triplet and quadruplet regimens in renal cell carcinoma: rationale, evidence, and challenges. Expert Review of Anticancer Therapy 23(2): 189–203, 2023.

83. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integrating ctDNA and molecular monitoring in metastatic renal cell carcinoma: from research to clinical practice.Frontiers in Oncology 13: 1121223, 2023.

84. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Translational advances in renal cell carcinoma immunotherapy: resistance mechanisms and novel biomarkers. Nature Reviews Urology 20(3): 168–186, 2023.

85. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Liquid biopsy applications in kidney cancer: current status and future directions. European Urology Focus 9(2): 271–282, 2023.

86. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Patient selection for immunotherapy in metastatic renal cell carcinoma: clinical, molecular, and immune predictors.Cancer Treatment Reviews 114: 102497, 2023.

87. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. The evolving role of immunotherapy in non-clear-cell renal cell carcinoma: evidence and future challenges. Therapeutic Advances in Medical Oncology 15: 17588359231105133, 2023.

88. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Adjuvant immunotherapy in renal cell carcinoma: current evidence and future directions. European Urology 84(1): 38–48, 2023.

89. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Renal cell carcinoma and the tumor microenvironment: implications for therapy resistance and immune modulation.Nature Reviews Clinical Oncology 20(5): 304–321, 2023.

90. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Safety and quality-of-life outcomes with long-term immunotherapy in renal cell carcinoma: insights from clinical trials and real-world studies. Cancer Immunology Immunotherapy 72(7): 2101–2114, 2023.

91. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. The immunotherapy landscape in genitourinary malignancies: lessons learned and emerging frontiers. Frontiers in Immunology 14: 1134222, 2023.

92. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Clinical utility of biomarkers for immune-oncology drug development in renal cell carcinoma. Nature Medicine Reviews – Oncology 17(8): 541–559, 2023.

93. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. A new era in renal cell carcinoma: sequencing immunotherapy and targeted agents for optimal benefit. Expert Opinion on Pharmacotherapy 24(14): 1527–1541, 2023.

94. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Epigenetic modulation and immunotherapy in renal cell carcinoma: a translational perspective. Therapeutic Advances in Medical Oncology 15: 17588359231112984, 2023.

95. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in renal cell carcinoma. Cancer Treatment Reviews 115: 102503, 2023.

96. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Novel therapeutic targets and ongoing clinical trials in renal cell carcinoma. Oncogene 42(18): 1307–1323, 2023.

97. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Microbiome and immunotherapy response in renal cell carcinoma. Frontiers in Immunology 14: 1152291, 2023.

98. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Radiomics and artificial intelligence in renal cell carcinoma: toward precision immuno-oncology. Cancer Imaging 23(1): 75, 2023.

99. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Immunotherapy-based neoadjuvant and adjuvant strategies in renal cell carcinoma. European Urology Open Science 52: 110–121, 2023.

100. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Toward the personalization of immunotherapy in renal cell carcinoma: integrating genomic, transcriptomic, and immune data. Nature Communications 14(1): 4321, 2023.

101. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Circulating tumor DNA as a biomarker for immunotherapy response and resistance in renal cell carcinoma. Frontiers in Oncology 13: 1189472, 2023.

102. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integrating immunotherapy with local ablative treatments in oligometastatic renal cell carcinoma. Therapeutic Advances in Medical Oncology 15: 17588359231123212, 2023.

103. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. The role of hypoxia and angiogenesis in shaping immune resistance in renal cell carcinoma. Cancer Letters 558: 216015, 2023.

104. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Artificial intelligence in renal cancer immunotherapy: predictive models and clinical applications. Expert Opinion on Drug Metabolism & Toxicology 19(5): 317–331, 2023.

105. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Role of immune checkpoint inhibitors in the treatment of advanced urothelial carcinoma: from first line to maintenance.Therapeutic Advances in Urology 15: 17562872231124752, 2023.

106. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. The role of microbiota in genitourinary cancers: impact on immunotherapy outcomes. Nature Reviews Urology 20(9): 573–589, 2023.

107. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Renal cell carcinoma: immune escape mechanisms and therapeutic strategies to counteract them. Cancer Treatment Reviews 116: 102506, 2023.

108. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Immuno-oncology drug sequencing: lessons learned from renal cell carcinoma. Expert Review of Anticancer Therapy23(9): 987–1002, 2023.

109. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. The impact of sarcopenia and cachexia on outcomes with immunotherapy in renal cell carcinoma. Cancer Immunology Immunotherapy 73(1): 55–69, 2024.

110. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Tumor-immune metabolism interplay in renal cell carcinoma: opportunities for therapeutic targeting. Nature Reviews Cancer 24(2): 112–130, 2024.

111. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Long-term survival with immunotherapy combinations in metastatic renal cell carcinoma: updated meta-analysis.European Urology 85(2): 175–190, 2024.

112. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integrating radiotherapy and immunotherapy in renal cell carcinoma: mechanisms and clinical perspectives. Therapeutic Advances in Medical Oncology 16: 17588359241112302, 2024.

113. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Multimodal management of oligoprogressive renal cell carcinoma under immunotherapy. Frontiers in Oncology 14: 1232107, 2024.

114. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Defining endpoints and surrogates for immunotherapy trials in renal cell carcinoma. Nature Reviews Clinical Oncology21(3): 172–187, 2024.

115. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. PD-L1 expression dynamics and clinical outcomes with immune checkpoint inhibitors in renal cell carcinoma. Journal for Immunotherapy of Cancer 12(1): e008763, 2024.

116. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. T-cell exhaustion and reinvigoration in renal cell carcinoma: translational insights for immunotherapy. Cancer Research84(4): 622–639, 2024.

117. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Emerging treatment paradigms in advanced renal cell carcinoma: the role of peri-operative immunotherapy. European Urology Open Science 54: 88–97, 2024.

118. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Clinical sequencing and precision oncology in renal cell carcinoma: real-world implementation and future perspectives.Cancer Discovery 14(5): 983–999, 2024.

119. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Health-related quality of life with immunotherapy combinations in metastatic renal cell carcinoma. Clinical Genitourinary Cancer 22(2): 153–162, 2024.

120. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Long-term safety and immune-related adverse events in renal cell carcinoma immunotherapy. Therapeutic Advances in Medical Oncology 16: 17588359241116589, 2024.

121. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Evolving patterns of resistance to immune checkpoint inhibitors in renal cell carcinoma. Cancer Treatment Reviews 117: 102512, 2024.

122. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Tumor mutational burden and immunotherapy efficacy in renal cell carcinoma. Nature Communications 15(1): 2312, 2024.

123. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Adaptive resistance mechanisms under immune checkpoint blockade in renal cell carcinoma. Frontiers in Oncology 14: 1298854, 2024.

124. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Emerging data on triplet therapy in metastatic renal cell carcinoma. Therapeutic Advances in Medical Oncology 16: 17588359241127890, 2024.

125. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. The role of VEGFR inhibition in modulating immune microenvironment in renal cancer. Journal for Immunotherapy of Cancer 12(5): e010882, 2024.

126. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Renal cell carcinoma immunotherapy in the real world: multicenter European experience. European Urology Focus10(3): 407–418, 2024.

127. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. PD-1/PD-L1 inhibitors in non-clear-cell renal cell carcinoma: pooled analysis of clinical outcomes. Clinical Genitourinary Cancer 22(4): 281–293, 2024.

128. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integrating immunotherapy biomarkers into daily oncology practice: renal cell carcinoma as a model. Nature Reviews Clinical Oncology 21(6): 443–460, 2024.

129. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Liver metastases in renal cell carcinoma: biological implications and response to immunotherapy. Cancer Treatment Reviews 118: 102521, 2024.

130. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Therapeutic implications of tumor heterogeneity in renal cell carcinoma. Expert Review of Molecular Diagnostics 24(3): 197–212, 2024.

131. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. New frontiers in combination immunotherapy for renal cell carcinoma. Frontiers in Immunology 15: 1384423, 2024.

132. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Metabolic reprogramming and immunotherapy resistance in renal cell carcinoma. Nature Reviews Urology 21(8): 651–668, 2024.

133. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Clinical trials update in renal cell carcinoma: 2024 overview of ongoing phase III studies. Therapeutic Advances in Medical Oncology 16: 17588359241131112, 2024.

134. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Harnessing novel immune pathways in renal cell carcinoma: TIGIT, LAG-3 and beyond. Expert Opinion on Biological Therapy 24(9): 1007–1020, 2024.

135. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integration of immunotherapy into multidisciplinary renal cancer care. European Urology Oncology 7(5): 780–795, 2024.

136. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. CTLA-4 and PD-1 dual inhibition in advanced renal cell carcinoma: evolving clinical landscape. Frontiers in Oncology14: 1421091, 2024.

137. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Expanding horizons in peri-operative immunotherapy for renal cell carcinoma. Nature Reviews Clinical Oncology21(10): 731–749, 2024.

138. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Artificial intelligence-guided immunotherapy selection in renal cell carcinoma. Frontiers in Artificial Intelligence 7: 1442018, 2024.

139. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Future perspectives on precision immunotherapy in renal cell carcinoma. Nature Reviews Urology 21(11): 789–808, 2024.

140. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integration of omics-based biomarkers into renal cancer immunotherapy. Cancer Immunology, Immunotherapy 73(12): 2285–2302, 2024.

141. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Harnessing bispecific antibodies and novel immune engagers in renal cell carcinoma. Therapeutic Advances in Medical Oncology 17: 17588359241135922, 2024.

142. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integrating radiomics and artificial intelligence to guide immunotherapy decisions in renal cell carcinoma. Nature Reviews Urology 21(12): 833–850, 2024.

143. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Clinical impact of immune-related adverse events on survival outcomes in renal cell carcinoma patients treated with checkpoint inhibitors. European Urology Open Science 56: 120–132, 2024.

144. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Emerging strategies to modulate the tumor immune microenvironment in renal cell carcinoma. Cancer Immunology Research 12(1): 78–95, 2024.

145. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Dynamic biomarkers of response and resistance during immunotherapy in renal cell carcinoma. Frontiers in Oncology14: 1504122, 2024.

146. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Optimizing immunotherapy sequencing in metastatic renal cell carcinoma: expert consensus recommendations. European Urology Oncology 7(8): 1023–1041, 2024.

147. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Liquid biopsy to monitor immunotherapy outcomes in renal cell carcinoma: challenges and opportunities. Therapeutic Advances in Medical Oncology 17: 17588359241140112, 2024.

148. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Epigenetic regulation of immune response in renal cell carcinoma. Frontiers in Immunology 15: 1533121, 2024.

149. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Tumor evolution under immune checkpoint blockade in renal cell carcinoma. Nature Reviews Cancer 24(12): 1011–1029, 2024.

150. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Spatial and temporal dynamics of immune infiltration in renal cell carcinoma. Cancer Cell 42(11): 883–900, 2024.

151. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integrating microbiome profiling in immunotherapy decision-making for renal cell carcinoma. Nature Medicine 30(12): 2042–2057, 2024.

152. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Predictive and prognostic biomarkers in renal cell carcinoma immunotherapy: an updated review. Cancer Treatment Reviews 119: 102541, 2025.

153. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Innovations in immunotherapy combinations for advanced renal cell carcinoma. Nature Reviews Urology 22(1): 44–61, 2025.

154. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. AI-driven clinical trial design in immuno-oncology: renal cell carcinoma as a model. Frontiers in Artificial Intelligence 8: 1593822, 2025.

155. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. The future of immunotherapy biomarkers: lessons from renal cell carcinoma. Nature Reviews Clinical Oncology 22(2): 112–128, 2025.

156. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Metabolic and immune crosstalk in the renal cancer microenvironment. Cancer Immunology, Immunotherapy 74(2): 255–273, 2025.

157. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Precision immunotherapy and molecular subtyping in renal cell carcinoma: where are we headed? Therapeutic Advances in Medical Oncology 17: 17588359241153312, 2025.

158. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Long-term outcomes with dual checkpoint inhibition in renal cell carcinoma: 5-year real-world data. European Urology86(3): 432–445, 2025.

159. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Future challenges and opportunities in immunotherapy sequencing for renal cell carcinoma. Nature Reviews Urology22(3): 189–205, 2025.

160. M. Ciccarese, F. Massari, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Integration of liquid biopsy and multi-omics data in renal cancer immunotherapy trials. Frontiers in Oncology 15: 1682744, 2025.

161. F. Massari, M. Ciccarese, F. Santoni, F. Maines, C. Santoni, D. Santini, G. Martignoni, E. Bria, G. Tortora, C. Porta. Clinical evolution of immunotherapy in renal cell carcinoma: ten years of transformation. Nature Reviews Clinical Oncology 22(5): 383–401, 2025.

Full papers:

1. Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D’Errico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni AA. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocrine-Related Cancer. 2009;16:1241–1249.

2. Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E, on behalf of ISA Co-Authors° (Massari F). Italian survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer. 2011;73:78–88.

3. Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, Brunelli M, Chilosi M, Tortora G, Bria E. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. Journal of Experimental & Clinical Cancer Research. 2011;30(1):115.

4. Brunelli M, Bria E, Nottegar A, Cingarlini S, Simionato F, Caliò A, Eccher A, Parolini C, Iannucci A, Gilioli E, Pedron S, Massari F, Tortora G, Borze I, Knuutila S, Gobbo S, Santo A, Tondulli L, Calabrò F, Martignoni G, Chilosi M. True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. PLoS One. 2012;7(12):e49689. doi:10.1371/journal.pone.0049689.

5. Brunello E, Brunelli M, Bogina G, Caliò A, Manfrin E, Nottegar A, Vergine M, Molino A, Bria E, Massari F, Tortora G, Cingarlini S, Pedron S, Chilosi M, Zamboni G, Miller K, Martignoni G, Bonetti F. FGFR1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. Journal of Experimental & Clinical Cancer Research.2012;31(1):103. doi:10.1186/1756-9966-31-103.

6. Massari F, Maines F, Modena A, Brunelli M, Bria E, Artibani W, Martignoni G, Tortora G. Castration-resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. Anti-Cancer Agents in Medicinal Chemistry.2013;13:872–886.

7. Bria E, Bonomi M, Pilotto S, Massari F, Novello S, Levra MG, Tortora G, Scagliotti G. Clinical meta-analyses of targeted therapies in adenocarcinoma. Targeted Oncology. 2013;8(1):35–45.

8. Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E. Profiling non-small cell lung cancer patients for treatment with crizotinib according to ALK abnormalities: translating science into medicine. Expert Opinion on Pharmacotherapy. 2013;14(5):597–608. doi:10.1517/14656566.2013.778828.

9. Iacovelli R, Cartenì G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri E, Berruti A, Cerbone L, Procopio G. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. European Journal of Cancer. 2013;49:2134–2142.

10. Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anti-Cancer Drugs. 2013;24(6):535–554. doi:10.1097/CAD.0b013e3283609ec1.

11. Massari F, Bria E, Maines F, Milella M, Giannarelli D, Cognetti F, Pappagallo G, Tortora G, Porta C. Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. Clinical Genitourinary Cancer. 2013;11(4):471–476.

12. Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. British Journal of Cancer.2013;109(3):686–693. doi:10.1038/bjc.2013.360.

13. Pilotto S, Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. Journal of Thoracic Oncology. 2013;8(12):e105–e106. doi:10.1097/JTO.0b013e3182a00e37.

14. Brunelli M, Manfrin E, Bria E, Massari F, Tortora G, Brunello E, Carbognin L, Nottegar A, Furlanetto J, Molino A, Fiorio E, Chilosi M, Jasani B, Vergine M, Marcolini L, Filippini D, Scarpa A, Martignoni G, Bonetti F. HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapy. Anticancer Research. 2013;33(9):3705–3710.

15. Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy. 2013;62(12):1757–1768. doi:10.1007/s00262-013-1487-6.

16. Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. Heterogeneous drug target expression as a possible basis for different clinical and radiological responses to treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Reviews.2014;33(1):321–331. doi:10.1007/s10555-013-9453-5.

17. Pilotto S, Bonomi M, Massari F, Milella M, Ciuffreda L, Brunelli M, Fassan M, Chilosi M, Scarpa A, Tortora G, Bria E. Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a ‘hard day’s night’. Current Pharmaceutical Design. 2014;20(24):3958–3972.

18. Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving first-line tyrosine kinase inhibitors: sensitivity and meta-regression analysis of randomized trials. Critical Reviews in Oncology/Hematology. 2014;90:135–145.

19. Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M, De Giorgi U, Trementino L, Procopio G, Tortora G, Cascinu S. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. International Journal of Cancer. 2015;136(1):1–10.

20. De Bari B, Fiorentino A, Greto D, Ciammella P, Arcangeli S, Avuzzi B, D’Angelillo RM, Desideri I, Kirienko M, Marchiori D, Massari F, Fundoni C, Franco P, Filippi AR, Alongi F. Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian Young Radiation Oncologist Meeting. Tumori Journal. 2013;99(6):637–649. doi:10.1700/1390.15450.

21. Maines F, Pilotto S, Milella M, Massari F, Vaccaro V, Felici A, Bria E, Tortora G. “Targeting” renal cell carcinoma patients with “targeted” agents: are we there yet? World Journal of Clinical Urology. 2014;3(1):9–19.

22. Massari F, Ciccarese C, Modena A, Maines F, Segala D, Luchini C, Marcolini L, Cavicchioli F, Cavalleri S, Bria E, Brunelli M, Martignoni G, Artibani W, Tortora G. Adenocarcinoma of the paraurethral glands: a case report. Histology and Histopathology. 2014;29(10):1295–1303.

23. Santoni M, Bracarda S, Nabissi M, Massari F, Conti A, Bria E, Tortora G, Santoni G, Cascinu S. CXC and CC chemokines as angiogenic modulators in non-haematological tumors. BioMed Research International.2014;2014:768758.

24. Santoni M, Massari F, Cascinu S. Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. Cellular & Molecular Immunology. 2015;12(1):122–124.

25. Bria E, Furlanetto J, Carbognin L, Brunelli M, Caliolo C, Nortilli R, Massari F, Pedron S, Manfrin E, Pellini F, Bonetti F, Sperduti I, Pollini GP, Scarpa A, Tortora G. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index and topoisomerase II-α co-amplification as predictors of pathological complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel. Clinical Breast Cancer.2015;15(1):16–23.

26. Massari F, Ciccarese C, Porcaro AB, Ferrero S, Gazzano G, Artibani W, Modena A, Bria E, Sava T, Caliò A, Novara G, Ficarra V, Chilosi M, Martignoni G, Bosari S, Cheng L, Tortora G, Brunelli M. Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. Pathology. 2014;46(6):523–526.

27. Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D’Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Alesini D, Zustovich F, Fraccon AP, Vicario G, Conteduca V, Maines F, Galligioni E. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. BJU International. 2015;115(5):764–771. doi:10.1111/bju.12857.

28. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Sunitinib, pazopanib or sorafenib for the treatment of patients with late-relapsing (>5 years) metastatic renal cell carcinoma. Journal of Urology. 2015;193(1):41–47.

29. Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma: correlation with overall survival, benchmarking and power analysis. Critical Reviews in Oncology/Hematology. 2015;93(1):50–59.

30. Iacovelli R, Farcomeni A, Sternberg CN, Cartenì G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Procopio G. Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. Journal of Urology. 2015;193(6):1905–1910. doi:10.1016/j.juro.2014.11.092.

31. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D’Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D’Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study. European Urology. 2015; 68(1):147–153. doi: 10.1016/j.eururo.2014.10.014.

32. Massari F, Maines F, Bria E, Galligioni E, Caffo O, Tortora G. Two-weekly docetaxel: issues for clinical practice.Cancer Biology & Therapy. 2015; 16(1):17–18.

33. Iacovelli R, Massari F, Albiges L, Loriot Y, Massard C, Fizazi K, Bernard E. Evidence and clinical relevance of tumor flare in patients who discontinued tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. European Urology. 2015; 68(1):154–160. doi: 10.1016/j.eururo.2014.10.034.

34. Bianconi M, Santoni M, Massari F, Faloppi L, Del Prete M, Giampieri R, Ciccarese C, Modena A, Tortora G, Scartozzi M, Cascinu S. Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice? Future Oncology. 2014; 10(14):2103–2106. doi: 10.2217/fon.14.185.

35. Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Annals of Surgical Oncology. 2015; 22(6):2094–2100. doi: 10.1245/s10434-014-4256-7.

36. Fiorini C, Massari F, Pedron S, Sanavio S, Ciccarese C, Porcaro AB, Artibani W, Bertoldo F, Zampini C, Sava T, Ficial M, Caliò A, Chilosi M, D’Amuri A, Sanguedolce F, Tortora G, Scarpa A, Delahunt B, Porta C, Martignoni G, Brunelli M. Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. American Journal of Cancer Research.2014; 4(6):907–915.

37. Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Prognostic significance of host immune status in patients with late-relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology. 2015; 10(4):549–556.

38. Massari F, Ciccarese C, Bimbatti D, Fantinel E, Modena A, Simbolo M, Brunelli M, Artibani W, Martignoni G, Scarpa A, Tortora G. Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy. Anti-Cancer Drugs. 2015; 26(4):469–473. doi: 10.1097/CAD.0000000000000208.

39. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.Cancer Treatment Reviews. 2015; 41(2):114–121. doi: 10.1016/j.ctrv.2014.12.013.

40. Buti S, Ciccarese C, Zanoni D, Santoni M, Modena A, Maines F, Gilli A, Bria E, Brunelli M, Rimanti A, Cascinu S, Ardizzoni A, Tortora G, Massari F. Prognostic factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? Future Oncology. 2015; 11(1):107–119. doi: 10.2217/fon.14.172.

41. Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G. The route to personalized medicine in bladder cancer: where do we stand? Targeted Oncology.2015; 10(3):325–336.

42. Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Bladder cancer: molecular determinants of personalized therapy. Current Drug Targets. 2015; 16(2):115–124.

43. Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Cartenì G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, Santini D. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? Journal of Experimental & Clinical Cancer Research. 2015; 34:10. doi: 10.1186/s13046-015-0122-0.

44. Santoni M, Massari F, Del Re M, Ciccarese C, Piva F, Principato G, Montironi R, Santini D, Danesi R, Tortora G, Cascinu S. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. Expert Opinion on Investigational Drugs. 2015; 24(6):809–824. doi: 10.1517/13543784.2015.1020370.

45. Caffo O, Ortega C, Di Lorenzo G, Sava T, De Giorgi U, Cavaliere C, Macrini S, Spizzo G, Aieta M, Messina C, Tucci M, Lodde M, Mansueto G, Zucali PA, Alesini D, D’Angelo A, Massari F, Morelli F, Procopio G, Ratta R, Fratino L, Lo Re G, Pegoraro MC, Zustovich F, Vicario G, Ruatta F, Federico P, La Russa F, Burgio SL, Maines F, Veccia A, Galligioni E. Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger. Urologic Oncology. 2015; 33(6):265.e15–21. doi: 10.1016/j.urolonc.2015.02.016.

46. Santoni M, Conti A, Piva F, Massari F, Ciccarese C, Burattini L, Cheng L, Lopez-Beltran A, Scarpelli M, Santini D, Tortora G, Cascinu S, Montironi R. Role of STAT3 pathway in genitourinary tumors. Future Science OA. 2015; 1(1):FSO15.

47. Ciccarese C, Modena A, Tortora G, Massari F. Kidney cancer and 2014: is innovation really over? Future Oncology.2015; 11(9):1437–1449.

48. Ciccarese C, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Conti A, Tortora G, Cascinu S, Montironi R. Present and future of personalized medicine in adult genitourinary tumors. Future Oncology. 2015; 11(9):1381–1388.

49. Massari F, Santoni M, Ciccarese C, Brunelli M, Conti A, Santini D, Montironi R, Cascinu S, Tortora G. Emerging concepts on drug resistance in bladder cancer: implications for future strategies. Critical Reviews in Oncology/Hematology. 2015; 95(2):81–89. doi: 10.1016/j.critrevonc.2015.05.005.

50. Ciccarese C, Massari F, Santoni M, Heng DY, Sotte V, Brunelli M, Conti A, Cheng L, Lopez-Beltran A, Scarpelli M, Cascinu S, Tortora G, Montironi R. New molecular targets in non-clear renal cell carcinoma: an overview of ongoing clinical trials. Cancer Treatment Reviews. 2015; 41(7):614–622. doi: 10.1016/j.ctrv.2015.05.006.

51. Massari F, Bria E, Ciccarese C, Munari E, Modena A, Zambonin V, Sperduti I, Artibani W, Cheng L, Martignoni G, Tortora G, Brunelli M. Prognostic value of beta-tubulin-3 and c-MYC in muscle invasive urothelial carcinoma of the bladder. PLoS One. 2015;10(6):e0127908. doi:10.1371/journal.pone.0127908.

52. Massari F, Santoni M, Ciccarese C, Santini D. The immunocheckpoints in modern oncology: the next 15 years. Expert Opinion on Biological Therapy. 2015;15(7):917–921.

53. Santoni M, Conti A, Andrikou K, Bittoni A, Lanese A, Pistelli M, Pantano F, Vincenzi B, Armento G, Massari F, Tonini G, Cascinu S, Santini D. Risk of pruritus in cancer patients treated with biological therapies: a systematic review and meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology. 2015;95(3):xxx–xxx. doi:10.1016/j.critrevonc.2015.05.007.

54. Ortolani S, Ciccarese C, Cingarlini S, Tortora G, Massari F. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. Future Oncology. 2015;11(12):1809–1828.

55. Ciccarese C, Ferrara R, Fantinel E, Zecchetto C, Simionato F, Grego E, Ortolani S, Caccese M, Bimbatti D, Cingarlini S, Brunelli M, Andreini A, Tortora G, Massari F. Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. Future Science OA. 2015;FSO29. doi:10.4155/FSO.15.27.

56. Ciccarese C, Massari F, Tortora G. Acquired hemophagocytic syndrome: comment to the case report. Future Science OA. 2015;FSO31. doi:10.4155/FSO.15.29.

57. Modena A, Ciccarese C, Fantinel E, Bimbatti D, Tortora G, Massari F. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. Expert Review of Anticancer Therapy. 2015;15(7):1–12.

58. Santoni M, Massari F, Iacovelli R, Ciccarese C, Verri E, Burattini L, Montironi R, Nolè F, Tortora G, Cascinu S. Inside the 2015 ASCO Genitourinary Cancers Symposium. Future Oncology. 2015;11(13):1859–1862.

59. Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics. 2015;15(9):xxx–xxx.

60. Massari F, Ciccarese C, Santoni M, Brunelli M, Piva F, Modena A, Bimbatti D, Fantinel E, Santini D, Cheng L, Cascinu S, Montironi R, Tortora G. Metabolic alterations in renal cell carcinoma. Cancer Treatment Reviews.2015;41:767–776.

61. Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group° (Massari F). Annals of Oncology. 2015;26(7):xxx–xxx.

62. Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, Verzoni E, Masini C, Massari F, Calvani N, Mosca A, Procopio G. Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Canadian Urological Association Journal. 2015;9(7–8):263–267.

63. Santoni M, Piva F, Scarpelli M, Cheng L, Lopez-Beltran A, Massari F, Iacovelli R, Berardi R, Santini D, Montironi R. The origin of prostate metastases: emerging insights. Cancer Metastasis Reviews. 2015;34(4):xxx–xxx.

64. Maines F, Caffo O, De Giorgi U, Fratino L, Lo Re G, Zagonel V, D’Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Basso U, Fraccon AP, Vicario G, Conteduca V, Galligioni E. Safety and clinical outcomes of abiraterone acetate after docetaxel in octogenarians with metastatic castration-resistant prostate cancer: results of the Italian Compassionate Use Named Patient Programme. Clinical Genitourinary Cancer. 2015;13(6):xxx–xxx. doi:10.1016/j.clgc.2015.07.019.

65. Conteduca V, Caffo O, Fratino L, Lo Re G, Basso U, D’Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Zagonel V, Veccia A, Lolli C, Maines F, De Giorgi U. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncology. 2015;11(16):xxx–xxx.

66. Piva F, Giulietti M, Occhipinti G, Santoni M, Massari F, Sotte V, Iacovelli R, Burattini L, Santini D, Montironi R, Cascinu S, Principato G. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget. 2015;6(35):xxx–xxx. doi:10.18632/oncotarget.5147.

67. Ciccarese C, Santoni M, Massari F, Modena A, Piva P, Conti A, Cheng L, Lopez-Beltran A, Scarpelli M, Tortora G, Montironi R. Metabolic alterations in renal and prostate cancer. Current Drug Metabolism. 2015;16(9):xxx–xxx.

68. Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S, Artibani W, Porcaro AB, Bimbatti D, Modena A, Sava T, Tortora G, Cheng L, Eccher A, Cima L, Pedron S, Ghimenton C, Martignoni G, Brunelli M. Reprofiling metastatic samples for chromosome 9p and 14q aberrations as a strategy to overcome tumor heterogeneity in clear-cell renal cell carcinoma. Applied Immunohistochemistry & Molecular Morphology. 2015;23(8):xxx–xxx.

69. Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, Licitra L, Montironi R, Tortora G, Massari F. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism & Toxicology. 2015;11(12):xxx–xxx.

70. Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosi M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Targeted Oncology. 2015;11(3):xxx–xxx.

71. Massari F, Ciccarese C, Santoni M, Lopez-Beltran A, Scarpelli M, Montironi R, Cheng L. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy. 2015;15(11):xxx–xxx.

72. Massari F, Modena A, Ciccarese C, Pilotto S, Maines F, Bracarda S, Sperduti I, Giannarelli D, Carlini P, Santini D, Tortora G, Porta C, Bria E. Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: sensitivity analysis of randomized trials. Critical Reviews in Oncology/Hematology.2015;98(2):xxx–xxx.

73. Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R, Holger M. Emerging immunotargets in metastatic renal cell carcinoma. Current Drug Targets. 2015;16(9):xxx–xxx.

74. Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. An overview of emerging immunotargets of genitourinary tumors. Current Drug Targets. 2015;16(10):xxx–xxx.

75. Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. AR-V7 and prostate cancer: the watershed for treatment selection? Cancer Treatment Reviews. 2016;43:27–35. doi:10.1016/j.ctrv.2015.12.003.

76. Ciccarese C, Massari F, Tortora G. Cabozantinib in advanced renal cell carcinoma: is it a METEOR? European Urology. 2015;69(1):xxx–xxx. doi:10.1016/j.eururo.2015.12.030.

77. Diminutto A, Basso U, Maruzzo M, Morelli F, De Giorgi U, Perin A, Fraccon AP, Lo Re G, Rizzi A, Sava T, Fornarini G, Valcamonico F, Zustovich F, Massari F, Zanardi E, Roma A, Zattoni F, Zagonel V. Adjuvant carboplatin treatment in 115 patients with stage I seminoma: retrospective multicenter survey. Clinical Genitourinary Cancer.2015;14(1):xxx–xxx. doi:10.1016/j.clgc.2015.12.009.

78. Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D’Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncology. 2016;12(4):xxx–xxx.

79. Ciccarese C, Santoni M, Massari F. Chemohormonal therapy in hormone-sensitive prostate cancer. New England Journal of Medicine. 2016;374(3):286–287.

80. Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A. Emerging immunotargets in bladder cancer. Current Drug Targets.2016;17(1):xxx–xxx.

81. Modena A, Massari F, Ciccarese C, Brunelli M, Santoni M, Montironi R, Martignoni G, Tortora G. Targeting MET and VEGFR axis in metastatic castration-resistant prostate cancer: ‘game over’? Targeted Oncology. 2016;11(2):xxx–xxx.

82. Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. Emerging immunotargets and immunotherapies in prostate cancer. Current Drug Targets. 2016;17(2):xxx–xxx.

83. Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R. Metabolic phenotype of bladder cancer. Cancer Treatment Reviews. 2016;45:46–57. doi:10.1016/j.ctrv.2016.03.005.

84. Ciccarese C, Massari F, Tortora G. 2015 and human cancer: back to overall survival. Future Oncology.2016;12(5):xxx–xxx.

85. Conteduca V, Crabb SJ, Scarpi E, Hanna C, Maines F, Joyce H, Fabbri P, Derosa L, Massari F, Lolli C, Zarif S, Jones RJ, Caffo O, Elliott T, De Giorgi U. Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration-resistant prostate cancer. Molecular Diagnosis & Therapy. 2016;20(3):xxx–xxx.

86. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, Di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. Risk of recurrence and conditional survival in complete responders treated with TKIs ± locoregional therapies for metastatic renal cell carcinoma. Oncotarget. 2016;7(18):xxx–xxx. doi:10.18632/oncotarget.8302.

87. Montironi R, Santoni M, Massari F, Lopez-Beltran A, Cheng L, Berardi R, Scarpelli M. Editorial: emerging immunotargets in genitourinary tumors. Current Drug Targets. 2016;17(7):748–749.

88. Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Ciccarese C, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Immunotargeting and personalized therapies in genitourinary cancers. Future Oncology. 2016;12(7):xxx–xxx.

89. Minardi D, Mazzucchelli R, Scarpelli M, Massari F, Ciccarese C, Lopez-Beltran A, Cheng L, Montironi R. Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3. Future Oncology. 2016;12(8):xxx–xxx.

90. Modena A, Ciccarese C, Iacovelli R, Brunelli M, Montironi R, Fiorentino M, Tortora G, Massari F. Immune checkpoint inhibitors and prostate cancer: a new frontier? Oncology Reviews. 2016;10(1):293.

91. Schepisi G, Santoni M, Massari F, Gurioli G, Salvi S, Conteduca V, Montironi R, De Giorgi U. Urothelial cancer: inflammatory mediators and implications for immunotherapy. BioDrugs. 2016;30(4):xxx–xxx.

92. Ciccarese C, Nobili E, Grilli D, Casolari L, Rihawi K, Gelsomino F, Tortora G, Massari F. The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. Expert Review of Anticancer Therapy. 2016;16(6):xxx–xxx.

93. Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 – kidney cancer. Future Oncology. 2016;12(10):xxx–xxx.

94. Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 – prostate and bladder cancer. Future Oncology. 2016;12(10):xxx–xxx.

95. Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Raspollini MR, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Genitourinary cancers: molecular determinants for personalized therapies. Urologia. 2016;83(3):xxx–xxx. doi:10.5301/uro.5000187.

96. Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, Bimbatti D, Massari F, Martignoni G, Tortora G. Investigating BRCA mutations: a breakthrough in precision medicine of castration-resistant prostate cancer. Targeted Oncology. 2016;11(4):xxx–xxx.

97. Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, Maruzzo M, La Russa F, Wheater M, Berardi R, Galli L, De Giorgi U. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016;7(34):xxx–xxx. doi:10.18632/oncotarget.10515.

98. Conteduca V, Crabb SJ, Jones RJ, Caffo O, Elliott T, Scarpi E, Fabbri P, Derosa L, Massari F, Numico G, Zarif S, Hanna C, Maines F, Joyce H, Lolli C, De Giorgi U. Persistent neutrophil-to-lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS One. 2016;11(7):e0158952. doi:10.1371/journal.pone.0158952.

99. Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, Tortora G, Massari F. The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews. 2016;49:37–44. doi:10.1016/j.ctrv.2016.07.003.

100. Ciccarese C, Di Nunno V, Montironi R, Fiorentino M, Brunelli M, Tortora G, Ardizzoni A, Massari F. The role of precision medicine for the treatment of metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development. 2016;1(4):369–377.

101. Montironi R, Gasparrini S, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montorsi F, Scarpelli M. Re: Karim A. Touijer, James A. Eastham. The sentinel lymph node concept and novel approaches in detecting lymph node metastasis in prostate cancer. European Urology. 2016; pii: S0302-2838(16)30503-6. doi:10.1016/j.eururo.2016.08.036.

102. Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, Bimbatti D, Scarpa A, Iacovelli R, Porta C, Virinder S, Tortora G, Artibani W, Schiavina R, Ardizzoni A, Brunelli M, Knuutila S, Martignoni G. Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next-generation sequencing approach. Oncotarget.2016; doi:10.18632/oncotarget.12551.

103. Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F, Bianchi E, Massari F, Veccia A, Chiuri VE, Facchini G, De Giorgi U. Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Frontiers in Pharmacology. 2016;7:376. doi:10.3389/fphar.2016.00376.

104. Gasparrini S, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Lopez-Beltran A, Cheng L, Montironi R. Prostate cancer grading in 2016. Minerva Urologica e Nefrologica. 2016. [Epub ahead of print].

105. Ciccarese C, Tortora G, Montironi R, Massari F. Is there still an open window in metastatic castration-resistant prostate cancer immunotherapy horizon? Translational Cancer Research. 2016; doi:10.21037/tcr.2016.11.05.

106. Munari E, Cima L, Massari F, Bertoldo F, Porcaro AB, Caliò A, Riva G, Ciocchetta E, Ciccarese C, Modena A, Iacovelli R, Sava T, Eccher A, Ghimenton C, Tortora G, Artibani W, Novella G, Bogina G, Zamboni G, Sanguedolce F, D’Amuri A, Martignoni G, Brunelli M. Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases. International Journal of Biological Markers. 2017; doi:10.5301/jbm.5000246.

107. Cimadamore A, Scarpelli M, Piva F, Massari F, Gasparrini S, Doria A, Cheng L, Lopez-Beltran A, Montironi R. Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. Future Oncology. 2017; doi:10.2217/fon-2016-0481.

108. Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V, Giunchi F, Brunelli M, Tortora G. Prostate cancer heterogeneity: discovering novel molecular targets for therapy. Cancer Treatment Reviews. 2017;54:68–73. doi:10.1016/j.ctrv.2017.02.001.

109. Ciccarese C, Massari F, Blanca A, Tortora G, Montironi R, Cheng L, Scarpelli M, Raspollini MR, Vau N, Fonseca J, Lopez-Beltran A. TP53 and its potential therapeutic role as a target in bladder cancer. Expert Opinion on Therapeutic Targets. 2017;21(4):401–414. doi:10.1080/14728222.2017.1297798.

110. Montironi R, Lopez-Beltran A, Cheng L, Gasparrini S, Montironi MA, Massari F, Scarpelli M, Montorsi F. Re: Kenneth A. Iczkowski’s letter to the editor re: Karim A. Touijer, James A. Eastham: The sentinel lymph node concept and novel approaches in detecting lymph node metastasis in prostate cancer. European Urology. 2017;71:e73–e75. doi:10.1016/j.eururo.2017.02.032.

111. Ciccarese C, Montironi R, Iacovelli R, Massari F. Localized prostate cancer genotyping: another step towards personalized therapy. Translational Cancer Research. 2017;6(Suppl 2):S246–S248.

112. Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, Bracarda S, Santini D, Danesi R. The role of drug–drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews. 2017;55:71–82. doi:10.1016/j.ctrv.2017.03.001.

113. Conteduca V, Caffo O, Lolli C, Aieta M, Scarpi E, Bianchi E, Maines F, Schepisi G, Salvi S, Massari F, Carrozza F, Veccia A, Chiuri VE, Campadelli E, Facchini G, De Giorgi U. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. The Prostate. 2017; doi:10.1002/pros.23357.

114. Bianconi M, Faloppi L, Lopez-Beltran A, Cheng L, Cimadamore A, Gasparrini S, Massari F, Scarpelli M, Montironi R. Immunotherapy in genitourinary cancers: where are we going? Expert Review of Precision Medicine and Drug Development. 2017.

115. Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori Journal. 2017; doi:10.5301/tj.5000625.

116. Blanca A, Cheng L, Montironi R, Moch H, Massari F, Fiorentino M, Raspollini MR, Scarpelli M, Lopez-Beltran A. miRNA expression in bladder cancer and their potential role in clinical practice. Current Drug Metabolism. 2017; doi:10.2174/1389200218666170518164507.

117. Montironi R, Cheng L, Moch H, Lopez-Beltran A, Scarpelli M, Massari F, Fiorentino M, Ciccarese C, Koch M, Kaimakliotis HZ, Wang L, Pili R, Mann SA. Targeting the programmed cell death-1 pathway in genitourinary tumors: current progress and future perspectives. Current Drug Metabolism. 2017; doi:10.2174/1389200218666170518162500.

118. Giunchi F, Ciccarese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Moch H, Massari F, Fiorentino M. Urinary biomarkers for prostate cancer. Current Drug Metabolism. 2017; doi:10.2174/1389200218666170518161140.

119. Ciccarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F. Circulating tumor cells: a reliable biomarker for prostate cancer treatment assessment? Current Drug Metabolism. 2017; doi:10.2174/1389200218666170518163549.

120. Cubelli M, Di Nunno V, Rihawi K, Massari F. Immune checkpoint inhibitors for metastatic bladder cancer.Translational Cancer Research. 2017;6(Suppl 4):S720–S732. doi:10.21037/tcr.2017.05.36.

121. Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urologic Oncology. 2017; doi:10.1016/j.urolonc.2017.05.007.

122. Montironi R, Gasparrini S, Lopez-Beltran A, Cheng L, Massari F, Montorsi F, Scarpelli M. Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder endometriosis: a systematic review of pathogenesis, diagnosis, treatment, impact on fertility, and risk of malignant transformation. European Urology. 2017; doi:10.1016/j.eururo.2017.05.029.

123. Ciccarese C, Di Nunno V, Iacovelli R, Massari F. Future perspectives for personalized immunotherapy in renal cell carcinoma. Expert Opinion on Biological Therapy. 2017; doi:10.1080/14712598.2017.1339030.

124. Ciccarese C, Iacovelli R, Bria E, Modena A, Massari F, Brunelli M, Fantinel E, Bimbatti D, Zamboni GA, Artibani W, Tortora G. The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. Immunotherapy. 2017;9(7):579–587.

125. Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R. Pathology and molecular updates in tumors of the prostate: towards a personalized approach.Expert Review of Molecular Diagnostics. 2017; doi:10.1080/14737159.2017.1341314.

126. Di Nunno V, Cubelli M, Massari F. The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development. 2017.

127. Massari F, Ciccarese C, Hes O, Michal M, Caliò A, Fiorentino M, Giunchi F, D’Amuri A, Sanguedolce F, Sabbatini R, Guida A, Ardizzoni A, Porta C, Iacovelli R, Tortora G, Cima L, Ortega C, Lapini A, Martignoni G, Brunelli M. The tumor entity denominated “clear cell-papillary renal cell carcinoma” according to the WHO 2016 new classification has the clinical characteristics of a renal cell adenoma and harbors a benign outcome. Pathology & Oncology Research.2017; doi:10.1007/s12253-017-0271-x.

128. Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G. Addressing the best treatment for non-clear cell renal cell carcinoma: a meta-analysis of randomized clinical trials comparing VEGFR-TKIs versus mTOR-targeted therapies. European Journal of Cancer.2017;83:237–246.

129. Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R. Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian Journal of Andrology. 2017;19:1–5.

130. Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G, Tonini G. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. Oncotarget. 2017.

131. Cimadamore A, Gasparrini S, Scarpelli M, Doria A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montironi R. Epigenetic modifications and modulators in prostate cancer. Critical Reviews in Oncogenesis. 2017;21(5–6):395–406.

132. Montironi R, Gasparrini S, Cimadamore A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Moch H, Montorsi F, Scarpelli M. Variants and variations in epithelial renal cell tumors in adults: the pathologist’s point of view.European Urology Supplements. 2017.

133. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE Study Investigators (Massari F). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomized, double-blind, phase 3 trial. The Lancet. 2017;390(10109):2266–2277. doi:10.1016/S0140-6736(17)32365-6.

134. Montironi R, Gasparrini S, Cimadamore A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Moch H, Montorsi F, Scarpelli M. Morphologic variants of epithelial and neuroendocrine tumors of the prostate: the pathologist’s point of view. European Urology Supplements. 2017.

135. Massari F, Di Nunno V, Ciccarese C, Graham J, Porta C, Comito F, Cubelli M, Iacovelli R, Heng DY. Adjuvant therapy in renal cell carcinoma. Cancer Treatment Reviews. 2017;60:152–157.

136. Vau N, Volavsek M, Blanca A, Montironi R, Raspollini MR, Massari F, Cheng L, Scarpelli M, Lopez-Beltran A. Prospects for precision therapy of bladder urothelial carcinoma. Expert Review of Precision Medicine and Drug Development. 2017.

137. Montironi R, Cimadamore A, Massari F, Montironi MA, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M. Whole slide imaging of large-format histology in prostate pathology: potential for information fusion. Archives of Pathology & Laboratory Medicine. 2017;141(11):1460–1461.

138. Massari F, Di Nunno V, Ardizzoni A. Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results.European Urology. 2017.

139. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern Pathology. 2017;30(9):xxxx–xxxx. doi:10.1038/modpathol.2017.104.

140. Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R, Ardizzoni A. Circulating tumor cells in genitourinary tumors. Therapeutic Advances in Urology. 2017;9(12):xxx–xxx.

141. Ghedini P, Bossert I, Zanoni L, Ceci F, Graziani T, Castellucci P, Ambrosini V, Massari F, Nobili E, Melotti B, Musto A, Zoboli S, Antunovic L, Kirienko M, Chiti A, Mosconi C, Ardizzoni A, Golfieri R, Fanti S, Nanni C. Liver metastases from prostate cancer at 11C-choline PET/CT: a multicenter retrospective analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2017;44(11):1843–1850.

142. Massari F, Di Nunno V. Atezolizumab for platinum-treated metastatic urothelial carcinoma. The Lancet.2017;389(10064):xxxx–xxxx.

143. Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treatment Reviews. 2018;64:11–20. doi:10.1016/j.ctrv.2017.12.007.

144. Massari F, Di Nunno V. Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: outcomes by prior number of regimens. European Urology. 2018;73:462–468. doi:10.1016/j.eururo.2017.11.023.

145. Montironi R, Cimadamore A, Gasparrini S, Mazzucchelli R, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology, and possible relationships with intraductal carcinoma. Expert Review of Anticancer Therapy. 2018;18(1):xxx–xxx.

146. Di Nunno V, Santoni M, Massari F. Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomized, open-label, phase 1b trial. European Urology. 2018;74(3):405–415.

147. Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E, Bortolus R, Fratino L, Gobitti C, Lamaj E, Ghedini P, Lodi Rizzini E, Massari F, Dionisi V, Fanti S, Volterrani D, Monari F. 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: real-world experience. Tumori Journal. 2018;104(3):xxx–xxx.

148. Mosillo C, Ciccarese C, Bimbatti D, Fantinel E, Dalla Volta A, Bisogno I, Zampiva I, Santoni M, Massari F, Brunelli M, Montironi R, Tortora G, Iacovelli R. Renal cell carcinoma in one year: going inside the news of 2017 – a report of the main advances in RCC cancer research. Cancer Treatment Reviews. 2018;67:29–33.

149. Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E. Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program. Clinical Genitourinary Cancer. 2018;16(5):e935–e945. doi:10.1016/j.clgc.2018.03.014.

150. Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C. Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis? Clinical Genitourinary Cancer. 2018;16(5):e903–e911. doi:10.1016/j.clgc.2018.04.007.

151. Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anticancer Drugs.2018;29(6):557–563. doi:10.1097/CAD.0000000000000632.

152. Di Nunno V, Mollica V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F. Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. Anticancer Drugs.2018;29(6):564–568. doi:10.1097/CAD.0000000000000644.

153. Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. Tivozanib for the treatment of renal cell carcinoma. Expert Opinion on Pharmacotherapy. 2018;19(9):987–992. doi:10.1080/14656566.2018.1480722.

154. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context.2018;7:212528. doi:10.7573/dic.212528.

155. Massari F, Santoni M, Di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A, Gasparrini S, Scarpelli M, Battelli N, Montironi R. Adjuvant and neoadjuvant approaches for urothelial cancer: updated indications and controversies.Cancer Treatment Reviews. 2018;68:80–85. doi:10.1016/j.ctrv.2018.06.002.

156. Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Review of Molecular Diagnostics. 2018;18(8):645–659. doi:10.1080/14737159.2018.1490179.

157. Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F. A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. Anticancer Drugs. 2018;29(7):689–693. doi:10.1097/CAD.0000000000000663.

158. Di Nunno V, Santoni M, Cimadamore A, Battelli N, Massari F. Tumor, node, and metastasis staging system for urological malignancies: are we ready for the next step? European Urology. 2018;74(3):559–562. doi:10.1016/j.eururo.2018.06.050.

159. Di Nunno V, De Luca E, Buttigliero C, Tucci M, Vignani F, Gatto L, Zichi C, Ardizzoni A, Di Maio M, Massari F. Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2018;131:102–111. doi:10.1016/j.critrevonc.2018.07.004.

160. Massari F, Santoni M, Di Nunno V, Cimadamore A, Battelli N, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R. Quick steps toward precision medicine in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development. 2018;3(5):273–280.

161. Di Nunno V, Cimadamore A, Santoni M, Scarpelli M, Fiorentino M, Ciccarese C, Iacovelli R, Cheng L, Lopez-Beltran A, Massari F, Montironi R. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncology. 2018;14(24):2531–2541.

162. Massari F, Di Nunno V, Santoni M. Re: Arnaud Méjean et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma (CARMENA trial): is this the end of cytoreductive nephrectomy? European Urology Oncology.2018;1(4):317–319.

163. Di Nunno V, Santoni M, Massari F. Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? The Lancet Oncology. 2018;19(9):e437.

164. Di Nunno V, Santoni M, Massari F. New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: can we be satisfied with an advantage in metastasis-free survival? European Urology Oncology. 2018;1(5):377–379.

165. Prisciandaro M, Ratta R, Massari F, Fornarini G, Caponnetto S, Iacovelli R, De Giorgi U, Facchini G, Scagliarini S, Sabbatini R, Caserta C, Peverelli G, Mennitto A, Verzoni E, Procopio G. Safety and efficacy of cabozantinib for metastatic non-clear renal cell carcinoma: real-world data from an Italian managed access program. American Journal of Clinical Oncology. 2018;41(12):1218–1224. doi:10.1097/COC.0000000000000478.

166. Maines F, De Giorgi U, Procopio G, Facchini G, Fratino L, Sabbatini R, Gasparro D, Basso U, Mosillo C, Campadelli E, Massari F, Sava T, Sirotova S, Messina C, Scagliarini S, Conteduca V, Verzoni E, Rossetti S, Veccia A, Kinspergher S, Caffo O. Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian named patient program. Future Oncology. 2018;14(21):2161–2170. doi:10.2217/fon-2018-0113.

167. Di Nunno V, Gatto L, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Massari F. Recent advances in liquid biopsy in patients with castration-resistant prostate cancer. Frontiers in Oncology. 2018;8:397. doi:10.3389/fonc.2018.00397.

168. Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R. Predictive role of changes in tumor burden and IMDC class during active surveillance for metastatic renal cell carcinoma. Urologic Oncology. 2018;36(12):531.e19–531.e26. doi:10.1016/j.urolonc.2018.08.018.

169. Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C. Should CARMENA really change our attitude toward cytoreductive nephrectomy in metastatic renal cell carcinoma? A systematic review and meta-analysis in the era of targeted therapy. Targeted Oncology. 2018;13(6):705–714.

170. Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, Tursi M, Maio MD, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S. Influenza vaccine indication during therapy with immune checkpoint inhibitors: the INVIDIa study. Immunotherapy. 2018;10(14):1229–1239. doi:10.2217/imt-2018-0080.

171. Dieci MV, Massari F, Giusti R, Inno A, Lombardi G, Noto L, Passaro A, Pietrantonio F, Spada F, Valente M, Di Maio M, Torri V. Gender influence on professional satisfaction and gender issue perception among young oncologists: a survey of the AIOM Young Oncologists Working Group. ESMO Open. 2018;3:e000389. doi:10.1136/esmoopen-2018-000389.

172. Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The identification of immunological biomarkers in kidney cancers. Frontiers in Oncology. 2018;8:456. doi:10.3389/fonc.2018.00456.

173. Santoni M, Montironi R, Battelli N, Massari F. Reply to Michael Staehler et al.: lymphocyte phenotype and timing of radical nephrectomy in patients treated with immune checkpoint inhibitors for renal cell carcinoma. European Urology.2018;74(6):893–896. doi:10.1016/j.eururo.2018.10.031.

174. Di Nunno V, Gatto L, Fragomeno B, Cubelli M, Nobili E, Romano I, Santoni M, Pisconti M, Montironi R, Massari F. Combination immunotherapy in metastatic renal cell carcinoma: are we leaving something back? Future Oncology.2018;14(29):3015–3023.

175. Saeed O, Lopez-Beltran A, Fisher KW, Scarpelli M, Montironi R, Cimadamore A, Massari F, Santoni M, Cheng L. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines, and treatment implications. Journal of Clinical Pathology. 2018;72(5):297–302. doi:10.1136/jclinpath-2018-205471.

176. Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R. New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen (PSMA).Frontiers in Oncology. 2018;8:653. doi:10.3389/fonc.2018.00653.

177. Dalbeni A, Ciccarese C, Bevilacqua M, Benati M, Caimmi C, Cerrito L, Famà F, Iacovelli R, Mantovani A, Massari F, Meneguzzi A, Minuz P, Montagnana M, Orsolini G, Rossini M, Tortora G, Viapiana O, Fava C. Effects of antiangiogenetic drugs on microcirculation and macrocirculation in patients with advanced-stage renal cancer. Cancers.2019;11(1):30. doi:10.3390/cancers11010030.

178. Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, Scarpelli M, Montironi R, Massari F. Molecular mechanisms related to hormone inhibition resistance in prostate cancer. Cells. 2019;8(1):43. doi:10.3390/cells8010043.

179. Massari F, Di Nunno V. CheckMate 214 patient-reported outcomes: listening to our patients. The Lancet Oncology.2019;20(3):e128.

180. Di Nunno V, Frega G, Gatto L, Brandi G, Massari F. Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. Future Oncology. 2019;15(9):941–944.

181. Massari F, Di Nunno V, Santoni M, Gatto L, Mollica V, Porta C. Cytoreductive nephrectomy in the targeted therapy era: this is not the end. European Urology Oncology. 2019;2(2):111–113. doi:10.1016/j.euo.2019.01.005.

182. Massari F, Di Nunno V, Mollica V, Graham J, Gatto L, Heng D. Adjuvant tyrosine kinase inhibitors in treatment of renal cell carcinoma: a meta-analysis of available clinical trials. Clinical Genitourinary Cancer. 2019;17(3):e543–e551.

183. Cimadamore C, Gasparrini S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Emerging molecular technologies in renal cell carcinoma: liquid biopsy. Cancers. 2019;11(2):196. doi:10.3390/cancers11020196.

184. Iacovelli R, Ciccarese C, Fornarini G, Massari F, Bimbatti D, Mosillo C, Rebuzzi SE, Di Nunno V, Grassi M, Fantinel E, Ardizzoni A, Tortora G. Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. British Journal of Clinical Pharmacology. 2019;85(7):1518–1526. doi:10.1111/bcp.13895.

185. Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R. Genitourinary tumors: update on molecular biomarkers for diagnosis, prognosis, and prediction of response to therapy.Current Drug Metabolism. 2019;20(6):443–453. doi:10.2174/1389200220666190225124352.

186. Di Nunno V, Mollica V, Gatto L, Santoni M, Sorgentoni G, Battelli N, Massari F. Adjuvant therapy in renal cell carcinoma—Is pharmacogenomics assessment another element to select our patients? Annals of Translational Medicine.2019;7(7):142.

187. Di Nunno V, Santoni M, Gatto L, Mollica V, Massari F. Metastatic hormone-naïve prostate cancer: a multimodal approach for a heterogeneous disease. European Urology Oncology. 2019;2(3):289–291.

188. Cimadamore A, Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. Microbiome and cancers, with focus on genitourinary tumors. Frontiers in Oncology. 2019;9:178. doi:10.3389/fonc.2019.00178.

189. Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Brandi G. The human microbiota and prostate cancer: friend or foe? Cancers. 2019;11(4):459. doi:10.3390/cancers11040459.

190. Santoni M, Maiorani G, Faloppi L, Di Nunno V, Gatto L, Massari F, Battelli N. Optimizing renal function and outcome of patients with cT2 renal cell carcinoma. Annals of Translational Medicine. 2019;7(12):267.

191. Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G. The effect of a treatment delay on outcome in metastatic renal cell carcinoma. Urologic Oncology. 2019;37(7):458–465. doi:10.1016/j.urolonc.2019.03.005.

192. Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F. Novel therapeutic approaches and targets currently under evaluation for renal cell carcinoma: waiting for the revolution. Clinical Drug Investigation. 2019;39(6):573–586. doi:10.1007/s40261-019-00773-w.

193. Di Nunno V, Mollica V, Gatto L, Santoni M, Cosmai L, Porta C, Massari F. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy. 2019;11(7):631–643.

194. Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R. Circulating tumor cells in renal cell carcinoma: recent findings and future challenges. Frontiers in Oncology. 2019;9:228. doi:10.3389/fonc.2019.00228.

195. Mollica V, Di Nunno V, Massari F. Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma. Chinese Clinical Oncology. 2019;8(2):20.

196. Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, Battelli N, Brandi G, Massari F. BAP1 in solid tumors. Future Oncology. 2019;15(24):2809–2819.

197. Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F. Resistance to systemic agents in renal cell carcinoma: predict and overcome genomic strategies adopted by tumor. Cancers. 2019;11(6):830.

198. Di Nunno V, Massari F, Mollica V, Cimadamore A, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Another one in the chamber: cabozantinib for patients with metastatic non-clear cell renal cell carcinoma. Annals of Translational Medicine. 2019;7(13):290. doi:10.21037/atm.2019.06.06.

199. Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Caliò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F. A meta-analysis evaluating clinical outcomes of patients with renal cell carcinoma harboring chromosome 9p loss. Molecular Diagnosis & Therapy. 2019;23(5):677–685. doi:10.1007/s40291-019-00414-0.

200. Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. Clinical Genitourinary Cancer. 2019;17(5):e931–e938. doi:10.1016/j.clgc.2019.07.001.

201. Massari F, Di Nunno V, Santoni M, Gatto L, Caserta C, Morelli F, Zafarana E, Carrozza F, Mosca A, Mollica V, Iacovelli R, Sabbatini R, Porta C, Bracarda S. Toward a genome-based treatment landscape for renal cell carcinoma.Critical Reviews in Oncology/Hematology. 2019;142:141–152.

202. Santoni M, Cimadamore A, Massari F, Piva F, Aurilio G, Martignetti A, Scarpelli M, Di Nunno V, Gatto L, Battelli N, Cheng L, Lopez-Beltran A, Montironi R. Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers. Cancers. 2019;11(9):1225. doi:10.3390/cancers11091225.

203. Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Moch H. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies.Expert Review of Molecular Diagnostics. 2019;19(10):887–896. doi:10.1080/14737159.2019.1665510.

204. Cimadamore A, Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, Di Nunno V, Cheng L, Lopez-Beltran A, Montironi R. Prostate cancer pathology: what has changed in the last 5 years? Urologia Journal. 2019;86(4):171–180.

205. Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L. Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Review of Molecular Diagnostics. 2019;19(12):1139–1150. doi:10.1080/14737159.2019.1680284.

206. Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Mariani C, Battelli N, Montironi R, Massari F. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Expert Review of Molecular Diagnostics. 2019;19(12):1121–1130. doi:10.1080/14737159.2019.1684265.

207. Cimadamore A, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Annals of Translational Medicine. 2019;7(Suppl 6):S194. doi:10.21037/atm.2019.07.30.

208. Massari F, Di Nunno V, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: from poverty to the spoiled of choice. Immunotherapy. 2019;11(17):1467–1481. doi:10.2217/imt-2019-0115.

209. Dall’Olio FG, Di Nunno V, Massari F. Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors. Journal of Clinical Oncology. 2019;37(34):3547–3548. doi:10.1200/JCO.19.01728.

210. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE Study Investigators (Massari F). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated phase 3 results.The Lancet Oncology. 2019;20(11):1556–1568. doi:10.1016/S1470-2045(19)30668-0.

211. Di Nunno V, Mollica V, Schiavina R, Nobili E, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Improving IMDC prognostic prediction through evaluation of initial site of metastasis in patients with metastatic renal cell carcinoma. Clinical Genitourinary Cancer. 2019;17(6):e1162–e1169. doi:10.1016/j.clgc.2019.08.007.

212. Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Review of Molecular Diagnostics. 2020;20(3):251–261. doi:10.1080/14737159.2020.1699791.

213. Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68,077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy. 2020;18(3):179–187. doi:10.1080/14779072.2019.1704626.

214. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors. Cancers.2020;12(1):84. doi:10.3390/cancers12010084.

215. Di Nunno V, Mollica V, Massari F. N-MYC: a key gene promoting worse prostate cancer progression. Translational Cancer Research. 2019;8(8):E15–E17. doi:10.21037/tcr.2019.12.63.

216. Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R. Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors, and immunotherapy. Future Oncology. 2020;16(10):75–90. doi:10.2217/fon-2019-0685.

217. Di Nunno V, Santoni M, Mollica V, Conti A, Montironi R, Battelli N, Ardizzoni A, Massari F. Systemic treatment for metastatic hormone-sensitive prostate cancer: a comprehensive meta-analysis evaluating efficacy and safety in specific subgroups of patients. Clinical Drug Investigation. 2020;40(4):345–357. doi:10.1007/s40261-020-00888-5.

218. Cimadamore A, Scarpelli M, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R. Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view. Expert Opinion on Biological Therapy. 2020;20(5):531–543. doi:10.1080/14712598.2020.1733965.

219. Giunchi F, Franceschini T, Gruppioni E, Altimari A, Capizzi E, Massari F, Schiavina R, Brunelli M, Martignoni G, Fiorentino M. Similarities and differences between clear cell tubulo-papillary and conventional clear cell renal cell carcinoma: a comparative phenotypical and mutational analysis. Diagnostics. 2020;10(4):223. doi:10.3390/diagnostics10040223.

220. Aurilio G, Santoni M, Cimadamore A, Massari F, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Nolè F, Montironi R. Renal cell carcinoma: genomic landscape and clinical implications. Expert Review of Precision Medicine and Drug Development. 2020;5(3):175–189. doi:10.1080/23808993.2020.1733407.

221. Bersanelli M, Buti S, Banna GL, Giorgi U, Cortellini A, Rebuzzi SE, Tiseo M, Fornarini G, Mazzoni F, Panni S, Tursi M, Marino PD, Rossetti S, Rossi E, Tomao S, Luca E, Sorarù M, Mucciarini C, Atzori F, Torre L, Vitale MG, Martelli V, Sepe P, Mollica V, Vaccaro V, Schinzari G, Ficorella C, Massari F, Maestri A, Sabbatini R, Sava T, Maio MD, Verzoni E, Procopio G, Giannarelli D. Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunotherapy. 2020;12(2):151–159. doi:10.2217/imt-2019-0180.

222. Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, Huang K, Massari F, Lu X, Cimadamore A, Lopez-Beltran A, Cheng L. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Annals of Oncology.2020;31(12):1745–1757. doi:10.1016/j.annonc.2020.02.002.

223. Mollica V, Santoni M, Di Nunno V, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Montironi R, Massari F. Immunotherapy and radiation therapy in renal cell carcinoma. Current Drug Targets. 2020;21(10):954–964. doi:10.2174/1389450121666200311121540.

224. Cimadamore A, Massari F, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Moch H. PD-1 and PD-L1 inhibitors for the treatment of kidney cancer: the role of PD-L1 assay. Current Drug Targets. 2020;21(12):1172–1181. doi:10.2174/1389450121666200324151056.

225. Di Nunno V, Mollica V, Massari F. Cabazitaxel in metastatic prostate cancer. The New England Journal of Medicine.2020;382(13):1286. doi:10.1056/NEJMc2000990.

226. Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L. Morphologic, molecular, and clinical features of aggressive variant prostate cancer. Cells. 2020;9(5):1073. doi:10.3390/cells9051073.

227. Lamberti G, Brizzi MP, Pusceddu S, Gelsomino F, Di Meglio G, Massari F, Badalamenti G, Riccardi F, Ibrahim T, Ciccarese C, Buti S, Carnaghi C, Prinzi N, Panzuto F, Campana D. Perioperative chemotherapy in poorly differentiated neuroendocrine neoplasia of the bladder: a multicenter analysis. Journal of Clinical Medicine. 2020;9(5):1351. doi:10.3390/jcm9051351.

228. Massari F, Mollica V, Salvagni S, Tognetto M, Ardizzoni A. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patient care. Future Oncology. 2020;16(20):1485–1488. doi:10.2217/fon-2020-0401.

229. Vitale G, Lamberti G, Comito F, Di Nunno V, Massari F, Morelli MC, Ardizzoni A, Gelsomino F. Anti–programmed cell death-1 and anti–programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opinion on Biological Therapy. 2020;20(8):911–921. doi:10.1080/14712598.2020.1762562.

230. Donini M, Buti S, Massari F, Mollica V, Rizzo A, Montironi R, Bersanelli M, Santoni M. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. Expert Review of Anticancer Therapy. 2020;20(9):755–767. doi:10.1080/14737140.2020.1770601.

231. Mollica V, Rizzo A, Montironi R, Cheng L, Giunchi F, Schiavina R, Santoni M, Fiorentino M, Lopez-Beltran A, Brunocilla E, Brandi G, Massari F. Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma. Cancers. 2020;12(6):1449. doi:10.3390/cancers12061449.

232. Franceschini T, Capizzi E, Massari F, Schiavina R, Fiorentino M, Giunchi F. Immunohistochemical overexpression of HER2 does not always match with gene amplification in invasive bladder cancer. Pathology Research and Practice.2020;216(10):153012. doi:10.1016/j.prp.2020.153012.

233. Santoni M, Massari F, Cheng L, Cimadamore A, Scarpelli M, Montironi R, Lopez-Beltran A. PD-L1 inhibitors for the treatment of prostate cancer. Current Drug Targets. 2020;21(16):1642–1651. doi:10.2174/1389450121666200609142219.

234. Mollica V, Rizzo A, Massari F. Cytoreductive nephrectomy: to whom and when? European Urology Oncology.2020;3(6):774–776. doi:10.1016/j.euo.2020.05.011.

235. Caffo O, Zagonel V, Baldessari C, Berruti A, Bortolus R, Buti S, Ceresoli GL, Donini M, Ermacora P, Fornarini G, Fratino L, Masini C, Massari F, Mosca A, Mucciarini C, Procopio G, Tucci M, Verri E, Zucali P, Buttigliero C. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. Annals of Oncology. 2020;31(10):1419–1420. doi:10.1016/j.annonc.2020.06.005.

236. Cimadamore A, Aurilio G, Nolè F, Massari F, Scarpelli M, Santoni M, Lopez-Beltran A, Cheng L, Montironi R. Update on circulating tumor cells in genitourinary tumors with focus on prostate cancer. Cells. 2020;9(6):1495. doi:10.3390/cells9061495.

237. Aurilio G, Cimadamore A, Santoni M, Nolè F, Scarpelli M, Massari F, Lopez-Beltran A, Cheng L, Montironi R. New frontiers in prostate cancer treatment: are we ready for drug combinations with novel agents? Cells. 2020;9(6):1522. doi:10.3390/cells9061522.

238. Conteduca V, Caffo O, Scarpi E, Sepe P, Galli L, Fratino L, Maines F, Chiuri VE, Santoni M, Zanardi E, Massari F, Toma I, Lolli C, Schepisi G, Sbrana A, Kinspergher S, Cursano MC, Casadei C, Modonesi C, Santini D, Procopio G, De Giorgi U. Modulation in prostate cancer patients treated with androgen receptor-targeted therapy. Journal of Clinical Medicine. 2020;9(6):1950. doi:10.3390/jcm9061950.

239. Rizzo A, Mollica V, Massari F. Re: Expression of ACE2 and TMPRSS2, the SARS-CoV-2 receptor and co-receptor, in prostate epithelial cells. European Urology. 2020;78(2):312–314. doi:10.1016/j.eururo.2020.06.034.

240. Massari F, Mollica V. Re: Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations. European Urology. 2020;78(2):311. doi:10.1016/j.eururo.2020.06.013.

241. Mollica V, Rizzo A, Massari F. SAVOIR: from own goal to winning goal? European Urology Oncology.2020;3(6):773–774. doi:10.1016/j.euo.2020.05.011.

242. Mollica V, Rizzo A, Massari F. The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer.Future Oncology. 2020;16(27):2299–2302. doi:10.2217/fon-2020-0571.

243. Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Cabozantinib after previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis. Targeted Oncology. 2020;15(4):495–505. doi:10.1007/s11523-020-00732-y.

244. Massari F, Di Nunno V, Guida A, Costa Silva CA, Derosa L, Mollica V, Colomba E, Brandi G, Albiges L. Addition of primary metastatic site on bone, brain, and liver to IMDC criteria in patients with metastatic renal cell carcinoma: a validation study. Clinical Genitourinary Cancer. 2020;18(5):e529–e536. doi:10.1016/j.clgc.2020.06.003.

245. Maggio I, Mollica V, Del Governatore M, Giunchi F, Massucci M, Manuzzi L, Caira A, Fiorentino M, Brandi G, Massari F. Gallbladder metastasis from clear cell renal cell carcinoma: a rare site of presentation of metastatic disease.Journal of Case Reports. 2020;10(3):148–151.

246. Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2, and mTOR inhibitors. Expert Review of Anticancer Therapy. 2020;20(10):1045–1057. doi:10.1080/14737140.2020.1807334.

247. Massari F, Mollica V, Rizzo A, Cosmai L, Rizzo M, Porta C. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opinion on Drug Safety.2020;19(12):1557–1566. doi:10.1080/14740338.2020.1811226.

248. Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F. Is there a role for immunotherapy in prostate cancer? Cells. 2020;9(9):2051. doi:10.3390/cells9092051.

249. Loriot Y, Sternberg CN, Castellano D, Oosting SF, Dumez H, Huddart R, Vianna K, Gordoa TA, Skoneczna I, Fay AP, Nolè F, Massari F, Brasiuniene B, Maroto P, Fear S, Di Nucci F, de Ducla S, Choy E. Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. European Journal of Cancer. 2020;138:202–211. doi:10.1016/j.ejca.2020.07.023.

250. Santoni M, Massari F, Aurilio G, Mollica V, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Nolè F, Montironi R. Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy.2020;12(17):1279–1292. doi:10.2217/imt-2020-0144.

251. Cimadamore A, Cheng L, Scarpelli M, Lopez-Beltran A, Mollica V, Montironi R, Massari F. Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical outcome after progressing to frontline and second-line anti-PD-1/PD-L1 in advanced urothelial cancer. Eur Urol 2020;77:269–76. European Urology.2021;79:E17–E19.

252. Brandi G, Deserti M, Palloni A, Turchetti D, Zuntini R, Pedica F, Frega G, De Lorenzo S, Abbati F, Rizzo A, Di Marco M, Massari F, Tavolari S. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. Cancer Genetics. 2020;S2210-7762(20)30276-3. doi: 10.1016/j.cancergen.2020.10.001.

253. Rizzo A, Mollica V, Massari F. Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. European Urology Oncology. 2020;3:804–805. doi: 10.1016/j.euo.2020.10.005.

254. Rizzo A, Mollica V, Massari F. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. European Urology Oncology. 2020;3:806. doi: 10.1016/j.euo.2020.10.004.

255. Zong Y, Montironi R, Massari F, Jiang Z, Lopez-Beltran A, Wheeler T M, Scarpelli M, Santoni M, Cimadamore A, Cheng L. Intraductal carcinoma of the prostate: pathogenesis and molecular perspectives. European Urology Focus.2020; doi: 10.1016/j.euf.2020.10.007.

256. Dall’Olio F G, Rizzo A, Mollica V, Massucci M, Maggio I, Massari F. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2020; doi: 10.2217/imt-2020-0179.

257. Santoni M, Piva F, Porta C, Bracarda S, Heng D Y, Matrana M R, Grande E, Mollica V, Aurilio G, Rizzo M, Giulietti M, Montironi R, Massari F. Artificial neural networks as a way to predict future kidney cancer incidence in the United States. Clinical Genitourinary Cancer. 2020;S1558-7673(20)30250-0. doi: 10.1016/j.clgc.2020.10.008.

258. De Giglio A, Scorsetti M, Franceschini D, Massari F, Ardizzoni A. Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: a challenging case enhances the need for a multidisciplinary approach. European Journal of Cancer. 2020;143:75–77. doi: 10.1016/j.ejca.2020.10.024.

259. Mollica V, Rizzo A, Tassinari E, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single-center study.Anticancer Drugs. 2020;31(10):1043–1050. doi: 10.1097/CAD.0000000000001017.

260. Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells.2020;9(12):2653. doi: 10.3390/cells9122653.

261. Mollica V, Rizzo A, Massari F. Avelumab maintenance for urothelial carcinoma. New England Journal of Medicine.2020;383(25):2482. doi: 10.1056/NEJMc2032018.

262. Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel). 2021;13(1):131. doi: 10.3390/cancers13010131.

263. Giunchi F, Massari F, Altimari A, Gruppioni E, Nobili E, Fiorentino M, Ardizzoni A. Dual TMPRSS2:ERG fusion in a patient with lung and prostate cancers. Diagnostics (Basel). 2020;10(12):1109. doi: 10.3390/diagnostics10121109.

264. Massucci M, Mollica V, Rizzo A, Ventrella L, Maggio I, Manuzzi L, Gatto L, Brandi G, Massari F. Encephalic leukocytoclastic vasculitis during treatment with sunitinib for renal cell carcinoma: a case report. Medicines. 2021;8(1):5. doi: 10.3390/medicines8010005.

265. Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Cartenì G, Grande E, Matrana M R, Crabb S J, Vau N, Sorgentoni G, Cimadamore A, Montironi R, Battelli N. Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: a new prognostic factor?Diagnostics. 2021;11(1):138. doi: 10.3390/diagnostics11010138.

266. Rizzo A, Mollica V, Massari F. Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: a systematic review and meta-analysis. European Urology Focus. 2021;S2405-4569(21)00004-3. doi: 10.1016/j.euf.2021.01.003.

267. Franceschini T, Giunchi F, Mollica V, Altimari A, Capizzi E, Banfi M, Schiavina R, Fiorentino M, Massari F. Renal tumors with oncocytic and papillary features: a phenotypic and genotypic study. Diagnostics (Basel). 2021;11(2):184. doi: 10.3390/diagnostics11020184.

268. Mollica V, Rizzo A, Rosellini M, Marchetti A, Ricci A D, Cimadamore A, Scarpelli M, Bonucci C, Andrini E, Errani C, Santoni M, Montironi R, Massari F. Bone targeting agents in patients with metastatic prostate cancer: state of the art.Cancers (Basel). 2021;13(3):546. doi: 10.3390/cancers13030546.

269. de Velasco G, Ruiz-Granados Á, Reig O, Massari F, Climent Duran M A, Verzoni E, Graham J, Llarena R, De Tursi M, Donskov F, Iglesias C, Pandha H S, Del Muro X G, Procopio G, Oudard S, Castellano D, Albiges L. Outcomes of systemic targeted therapy in recurrent RCC treated with adjuvant sunitinib. BJU International. 2021;127(6):658–667. doi: 10.1111/bju.15356.

270. Santoni M, Massari F, Santoni G, Cimadamore A, Montironi R, Battelli N. Re: Human chimeric antigen receptor macrophages for cancer immunotherapy. European Urology. 2021;79(5):E131–E132. doi: 10.1016/j.eururo.2021.01.025.

271. Mollica V, Franceschini T, Gruppioni E, Rizzo A, Ricci C, Schiavina R, Brunocilla E, Ardizzoni A, Fiorentino M, Giunchi F, Massari F. Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. Pathology Research and Practice. 2021;219:153350. doi: 10.1016/j.prp.2021.153350.

272. Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. Treating prostate cancer by antibody-drug conjugates. International Journal of Molecular Sciences. 2021;22(4):1551. doi: 10.3390/ijms22041551.

273. Massari F, Rizzo A, Mollica V, Santoni M. A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? Future Oncology. 2021;17(11):1373–1376. doi: 10.2217/fon-2021-0089.

274. Santoni M, Miccini F, Cimadamore A, Piva F, Massari F, Cheng L, Lopez-Beltran A, Montironi R, Battelli N. An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opinion on Investigational Drugs. 2021;30(5):455–465. doi: 10.1080/13543784.2021.1891222.

275. Ciccarese F, Piccinino A, Brocchi S, Balacchi C, Dall’Olio F G, Massari F, Rihawi K, Paccapelo A, Ardizzoni A, Golfieri R. Expected and non-expected immune-related adverse events detectable by CT. European Journal of Radiology.2021;138:109617. doi: 10.1016/j.ejrad.2021.109617.

276. Rizzo A, Mollica V, Santoni M, Ricci A D, Rosellini M, Marchetti A, Montironi R, Ardizzoni A, Massari F. Impact of clinicopathological features on survival in patients treated with first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors for renal cell carcinoma: a meta-analysis of randomized clinical trials. European Urology Focus.2021;S2405-4569(21)00058-4. doi: 10.1016/j.euf.2021.03.001.

277. Rizzo A, Mollica V, Giunchi F, Dall’Olio F G, Rosellini M, Marchetti A, Franceschini T, Schiavina R, Brunocilla E, Fiorentino M, Ardizzoni A, Massari F. Impact of HER2 assessment by CISH in urothelial carcinoma: a retrospective single-center experience. Pathology Research and Practice. 2021;220:153410. doi: 10.1016/j.prp.2021.153410.

278. Rizzo A, Rosellini M, Marchetti A, Mollica V, Massari F. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy. 2021;13(9):767–776. doi: 10.2217/imt-2020-0323.

279. Motzer R, Alekseev B, Rha S Y, Porta C, Eto M, Powles T, Grünwald V, Hutson T E, Kopyltsov E, Méndez-Vidal M J, Kozlov V, Alyasova A, Hong S H, Kapoor A, Alonso Gordoa T, Merchan J R, Winquist E, Maroto P, Goh J C, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus C E, Smith A D, Dutta L, Mody K, Perini R F, Xing D, Choueiri T K; CLEAR Trial Investigators. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New England Journal of Medicine. 2021;384(14):1289–1300. doi: 10.1056/NEJMoa2035716.

280. Cimadamore A, Cheng L, Scarpelli M, Massari F, Mollica V, Santoni M, Lopez-Beltran A, Montironi R, Moch H. Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review.Translational Andrology and Urology. 2021;10(3):1506–1520. doi: 10.21037/tau-20-1150.

281. Aurilio G, Cimadamore A, Lopez-Beltran A, Scarpelli M, Massari F, Verri E, Cheng L, Santoni M, Montironi R. Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. Translational Andrology and Urology. 2021;10(3):1521–1529. doi: 10.21037/tau-20-1436.

282. Montironi R, Cheng L, Cimadamore A, Mazzucchelli R, Scarpelli M, Santoni M, Massari F, Lopez-Beltran A. Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the grade groups?Translational Andrology and Urology. 2021;10(3):1530–1540. doi: 10.21037/tau-20-853.

283. Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Schiavina R, Cheng L, Lopez-Beltran A, Brunocilla E, Montironi R, Massari F. TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like? A narrative review. Translational Andrology and Urology. 2021;10(3):1541–1552. doi: 10.21037/tau-20-1109.

284. Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R. Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. Translational Andrology and Urology. 2021;10(3):1562–1568. doi: 10.21037/tau-20-1439.

285. Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Cimadamore A, Montironi R, Massari F. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF? Translational Andrology and Urology. 2021;10(3):1581–1587. doi: 10.21037/tau-20-1125.

286. Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci A D, Fiorentino M, Battelli N, Santoni M, Massari F. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: a meta-analysis of prospective clinical trials. Pathology Research and Practice. 2021;222:153440. doi: 10.1016/j.prp.2021.153440.

287. Rizzo A, Mollica V, Dall’Olio F G, Ricci A D, Maggio I, Marchetti A, Rosellini M, Santoni M, Ardizzoni A, Massari F. Quality of life assessment in renal cell carcinoma phase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncology. 2021;17(12):1491–1502. doi: 10.2217/fon-2021-0069.

288. Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci A D, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy. 2021;13(9):777–789. doi: 10.2217/imt-2021-0005.

289. Santoni M, Massari F, Montironi R, Battelli N. Manipulating macrophage polarization in cancer patients: from nanoparticles to human chimeric antigen receptor macrophages. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. 2021;188547. doi: 10.1016/j.bbcan.2021.188547.

290. Cimadamore A, Rizzo A, Mollica V, Massari F, Lopez-Beltran A, Scarpelli M, Cheng L, Santoni M, Montironi R. An update on immunotherapy in uro-oncology. Expert Review of Precision Medicine and Drug Development. 2021;6(4):255–266. doi: 10.1080/23808993.2021.1911638.

291. Rizzo A, Mollica V, Massari F. Considerations regarding a network meta-analysis of systemic treatments for metastatic castration-sensitive prostate cancer. JAMA Oncology. 2021;7(8):1149–1150. doi: 10.1001/jamaoncol.2021.0960.

292. Rizzo A, Mollica V, Massari F. Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384:1125–35. European Urology Oncology. 2021;4(5):826–827. doi: 10.1016/j.euo.2021.04.010.

293. Santoni M, Rizzo A, Mollica V, Rosellini M, Marchetti A, Fragomeno B, Battelli N, Massari F. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2021;21(5):871–878. doi: 10.1080/14737167.2021.1937130.

294. Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi A B, Montironi R. Circulating tumor DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic. International Journal of Molecular Sciences. 2021;22(11):5522. doi: 10.3390/ijms22115522.

295. Basso U, Facchinetti A, Rossi E, Maruzzo M, Conteduca V, Aieta M, Massari F, Fraccon A P, Mucciarini C, Sava T, Santoni M, Pegoraro C, Durante E, Nicodemo M, Perin A, Bearz A, Gatti C, Fiduccia P, Diminutto A, Barile C, De Giorgi U, Zamarchi R, Zagonel V. Prognostic role of circulating tumor cells in metastatic renal cell carcinoma: a large, multicenter prospective trial. Oncologist. 2021;26(9):e1638–e1647. doi: 10.1002/onco.13842.

296. Rizzo A, Mollica V, Massari F. Adjuvant immunotherapy in muscle-invasive urothelial carcinoma. Lancet Oncology.2021;22(6):e237. doi: 10.1016/S1470-2045(21)00202-3.

297. Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The molecular characteristics of non-clear cell renal cell carcinoma: what’s the story morning glory? International Journal of Molecular Sciences. 2021;22(12):6237. doi: 10.3390/ijms22126237.

298. Rizzo A, Mollica V, Santoni M, Massari F. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. Expert Review of Gastroenterology & Hepatology. 2021;15(11):1203–1212. doi: 10.1080/17474124.2021.1948328.

299. Rizzo A, Dadduzio V, Ricci A D, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opinion on Investigational Drugs. 2021;30(8):877–884. doi: 10.1080/13543784.2021.1948532.

300. Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A, Santoni M. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. European Journal of Cancer. 2021;154:120–127. doi: 10.1016/j.ejca.2021.06.015.

301. Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Massari F, Santoni M, Scarpelli M, Cheng L, Montironi R. Prostate cancer in 2021: novelties in prognostic and therapeutic biomarker evaluation. Cancers (Basel).2021;13(14):3471. doi:10.3390/cancers13143471.

302. Mollica V, Brocchi S, Dall’Olio FG, Marcolin L, Paccapelo A, Santoni M, Rizzo A, Montironi R, Golfieri R, Massari F, Ardizzoni A. Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mRCC: when RECIST is not enough. Cancers (Basel). 2021;13(14):3492. doi:10.3390/cancers13143492.

303. Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Cabozantinib in pretreated patients with metastatic renal cell carcinoma with sarcomatoid differentiation: a real-world study. Target Oncology. 2021. doi:10.1007/s11523-021-00828-z.

304. Rizzo A, Oderda M, Mollica V, Merler S, Morelli F, Fragomeno B, Taveri E, Sorgentoni G, Santoni M, Massari F. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Anticancer Drugs. 2021. doi:10.1097/CAD.0000000000001168.

305. Ricci AD, Rizzo A, Mollica V, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data.Anticancer Drugs. 2021. doi:10.1097/CAD.0000000000001200.

306. Marchetti A, Rosellini M, Rizzo A, Mollica V, Battelli N, Massari F, Santoni M. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. Expert Opinion on Pharmacotherapy. 2021. doi:10.1080/14656566.2021.1959548.

307. Rizzo A, Merler S, Sorgentoni G, Oderda M, Mollica V, Gadaleta-Caldarola G, Santoni M, Massari F. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. Expert Opinion on Drug Metabolism & Toxicology. 2021. doi:10.1080/17425255.2021.1970745.

308. Rizzo A, Mollica V, Massari F. Randomized clinical trials in the era of precision oncology—the role of endpoints, industry funding, and medical writing integrity. JAMA Oncology. 2021. doi:10.1001/jamaoncol.2021.3335.

309. Mollica V, Rizzo A, Massari F. Adjuvant nivolumab in muscle-invasive urothelial carcinoma. New England Journal of Medicine. 2021;385(10):956–957. doi:10.1056/NEJMc2110897.

310. Mollica V, Rizzo A, Massari F. Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncology. In press; Eur Urol Oncol. 2021. doi:10.1016/j.euo.2021.06.008.

311. Rizzo A, Santoni M, Mollica V, Fiorentino M, Brandi G, Massari F. Microbiota and prostate cancer. Seminars in Cancer Biology. 2021. doi:10.1016/j.semcancer.2021.09.007.

312. Basso U, Procopio G, Fornarini G, Massari F, Bearz A, Fratino L, Milella M, Bassanelli M, Ermacora P, Bimbatti D, Verzoni E, Rizzo M, Porta C. Safety and efficacy of tivozanib in first-line mRCC: a multicenter compassionate-use study (Meet-Uro 16). Oncology. 2021. doi:10.1159/000515951.

313. Ricci C, Franceschini T, Giunchi F, Borsato M, Mollica V, Massari F, Fiorentino M. A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34. Pathology Research and Practice. 2021;227:153637. doi:10.1016/j.prp.2021.153637.

314. Aurilio G, Santoni M, Massari F, Cimadamore A, Rizzo A, Mollica V, Verri E, Battelli N, Montironi R. Metabolomic profiling in renal cell carcinoma patients: news and views. Cancers (Basel). 2021;13(20):5229. doi:10.3390/cancers13205229.

315. Bersanelli M, Buti S, Rizzo M, Cortellini A, Cattrini C, Massari F, Masini C, Vitale MG, Fornarini G, Caffo O, Atzori F, Gatti A, Macrini S, Mucciarini C, Galli L, Morelli F, Stellato M, Fanelli M, Corti F, Zucali PA, Toscani I, Dalla Volta A, Gernone A, Baldessari C, La Torre L, Zara D, Gennari A, Bracarda S, Procopio G, Porta C. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Therapeutic Advances in Urology. 2021;13:17562872211054302. doi:10.1177/17562872211054302.

316. Rizzo A, Mollica V, Santoni M, Massari F. Cancer immunotherapy: current and future perspectives on a therapeutic revolution. Journal of Clinical Medicine. 2021;10(22):5246. doi:10.3390/jcm10225246.

317. Ricci C, Franceschini T, Giunchi F, Grillini M, Ambrosi F, Massari F, Mollica V, Colecchia M, Fiorentino M. Immunohistochemical expression of preferentially expressed antigen in melanoma (PRAME) in the uninvolved background testis, germ cell neoplasia in situ, and germ cell tumors of the testis. American Journal of Clinical Pathology.2021. doi:10.1093/ajcp/aqab200.

318. Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma. Target Oncology. 2021. doi:10.1007/s11523-021-00861-y.

319. Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: an Italian case series. World Journal of Clinical Oncology. 2021;12(11):1037–1046. doi:10.5306/wjco.v12.i11.1037.

320. Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Massari F. Risk of toxicity with immunotherapy–tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future Oncology.2021. doi:10.2217/fon-2021-0888.

321. Nigro MC, Mollica V, Marchetti A, Cheng M, Rosellini M, Montironi R, Cheng L, Massari F. Current androgen receptor antagonists under investigation for resistant prostate cancer. Expert Review of Anticancer Therapy. 2021. doi:10.1080/14737140.2022.2020651.

322. Mollica V, Marchetti A, Rosellini M, Nuvola G, Rizzo A, Santoni M, Cimadamore A, Montironi R, Massari F. An insight on novel molecular pathways in metastatic prostate cancer: a focus on DDR, MSI and AKT. International Journal of Molecular Sciences. 2021;22(24):13519. doi:10.3390/ijms222413519.

323. Nuvola G, Rizzo A, Mollica V, Massari F. The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem? Immunotherapy. 2022. doi:10.2217/imt-2021-0324.

324. Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, Faloppi L, Battelli N, Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism & Toxicology. 2022. doi:10.1080/17425255.2021.2029405.

325. Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N, Massari F. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Critical Reviews in Oncology/Hematology. 2022. doi:10.1016/j.critrevonc.2022.103596.

326. Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncology. 2022. doi:10.2217/fon-2021-0841.

327. Santoni M, Massari F, Bracarda S, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N. Cabozantinib in patients with advanced renal cell carcinoma primary refractory to first-line immunocombinations or tyrosine kinase inhibitors. European Urology Focus.2022. doi:10.1016/j.euf.2022.02.004.

328. Marchetti A, Rosellini M, Nuvola G, Tassinari E, Mollica V, Rizzo A, Santoni M, Cimadamore A, Farolfi A, Montironi R, Fanti S, Massari F. PARP inhibitors and radiometabolic approaches in metastatic castration-resistant prostate cancer: what’s now, what’s new, and what’s coming? Cancers (Basel). 2022;14(4):907. doi:10.3390/cancers14040907.

329. Rizzo A, Mollica V, Santoni M, Palmiotti G, Massari F. Pathologic complete response in urothelial carcinoma patients receiving neoadjuvant immune checkpoint inhibitors: a meta-analysis. Journal of Clinical Medicine. 2022; 11(4):1038. doi: 10.3390/jcm11041038.

330. Ciccarese C, Iacovelli R, Buti S, Primi F, Astore S, Massari F, Ferrara M G, Palermo G, Foschi N, Iacovelli V, Rossi E, Schinzari G, Bove P, Bassi P, Bria E, Tortora G. Concurrent nivolumab and metformin in diabetic cancer patients: is it safe and more active? Anticancer Research. 2022; 42(3):1487–1493. doi: 10.21873/anticanres.15620.

331. Rebuzzi S E, Cerbone L, Signori A, Santoni M, Murianni V, De Giorgi U, Procopio G, Porta C, Milella M, Basso U, Massari F, Maruzzo M, Iacovelli R, Battelli N, Carmisciano L, Banna G L, Buti S, Fornarini G. Application of the MEET-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Therapeutic Advances in Medical Oncology. 2022; 14:17588359221079580. doi: 10.1177/17588359221079580.

332. Rizzo A, Mollica V, Massari F. Cabozantinib for treatment of brain metastases in patients with renal cell carcinoma.JAMA Oncology. 2022. doi: 10.1001/jamaoncol.2022.0049.

333. Medici F, Siepe G, Strigari L, Massari F, Buwenge M, Bisello S, Castellucci P, Fanti S, Cammelli S, Morganti A G. CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: a case report. Molecular and Clinical Oncology. 2022; 16(4):85. doi: 10.3892/mco.2022.2518.

334. Rebuzzi S E, Rescigno P, Catalano F, Mollica V, Vogl U M, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna G L, Fornarini G. Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives. Cancers (Basel). 2022; 14(5):1245. doi: 10.3390/cancers14051245.

335. Santoni M, Aurilio G, Massari F, Grande E, Matrana M R, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza I O, Mollica V, Rizzo A, Battelli N, Porta C. Nivolumab versus cabozantinib as second-line therapy in patients with advanced renal cell carcinoma: a real-world comparison. Clinical Genitourinary Cancer. 2022. doi: 10.1016/j.clgc.2022.02.003.

336. Mollica V, Nuvola G, Tassinari E, Nigro M C, Marchetti A, Rosellini M, Rizzo A, Errani C, Massari F. Bone-targeting agents in patients with prostate cancer: general toxicities and osteonecrosis of the jaw. Current Oncology. 2022; 29(3):1709–1722. doi: 10.3390/curroncol29030142.

337. Rizzo A, Mollica V, Santoni M, Massari F. Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis. Immunotherapy. 2022. doi: 10.2217/imt-2021-0261.

338. Smith M R, Hussain M, Saad F, Fizazi K, Sternberg C N, Crawford E D, Kopyltsov E, Park C H, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela T L J, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal M J, Maughan B L, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. New England Journal of Medicine. 2022; 386(12):1132–1142. doi: 10.1056/NEJMoa2119115.

339. Santoni M, Molina-Cerrillo J, Massari F, Montironi R, Grande E. Re: Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. European Urology. 2022. doi: 10.1016/j.eururo.2022.03.017.

340. Rizzo A, Mollica V, Merler S, Morelli F, Sorgentoni G, Oderda M, Santoni M, Massari F. Incidence of grade 3–4 adverse events, dose reduction and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. Expert Opinion on Drug Metabolism & Toxicology. 2022. doi: 10.1080/17425255.2022.2072727.

341. Di Sciascio L, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Massari F, Bianchi F M, Colecchia M, Fiorentino M, Ricci C. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions? Pathology Research and Practice. 2022; 234:153937. doi: 10.1016/j.prp.2022.153937.

342. Santoni M, Massari F, Rizzo A, Mollica V, Cimadamore A, Montironi R, Battelli N. Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number-needed-to-treat analysis. Tumori Journal. 2022. doi: 10.1177/03008916221090323.

343. Mollica V, Massari F, Rizzo A, Ferrara R, Menta A K, Adashek J J. Genomics and immunomics in the treatment of urothelial carcinoma. Current Oncology. 2022; 29(5):3499–3518. doi: 10.3390/curroncol29050283.

344. Brunelli M, Martignoni G, Malpeli G, Volpe A, Cima L, Raspollini M R, Barbareschi M, Tafuri A, Masi G, Barzon L, Ammendola S, Villanova M, Cerruto M A, Milella M, Buti S, Bersanelli M, Fornarini G, Rebuzzi S E, … Massari F, Rizzo M, Franco R, Fassan M, Porta C, Antonelli A. Validation of a novel three-dimensional (3D fusion) gross sampling protocol for clear cell renal cell carcinoma to overcome intratumoral heterogeneity: the MEET-URO 18 study. Journal of Personalized Medicine. 2022; 12(5):727. doi: 10.3390/jpm12050727.

345. Rizzo A, Santoni M, Mollica V, Ricci A D, Calabrò C, Cusmai A, Gadaleta-Caldarola G, Palmiotti G, Massari F. The impact of concomitant proton pump inhibitors on immunotherapy efficacy among patients with urothelial carcinoma: a meta-analysis. Journal of Personalized Medicine. 2022; 12(5):842. doi: 10.3390/jpm12050842.

346. Raschi E, Fusaroli M, Massari F, Mollica V, Repaci A, Ardizzoni A, Poluzzi E, Pagotto U, Di Dalmazi G. The changing face of drug-induced adrenal insufficiency in the FDA adverse event reporting system. Journal of Clinical Endocrinology & Metabolism. 2022. doi: 10.1210/clinem/dgac359.

347. Santoni M, Monteiro F S M, Massari F, Abahssain H, Aurilio G, Morillo J, Myint Z W, Zabalza I O, Battelli N, Grande E. Statins and renal cell carcinoma: antitumor activity and influence on cancer risk and survival. Critical Reviews in Oncology/Hematology. 2022. doi: 10.1016/j.critrevonc.2022.103731.

348. Tassinari E, Mollica V, Nuvola G, Marchetti A, Rosellini M, Massari F. Treatment options for metastatic urothelial carcinoma after first-line chemotherapy. Cancer Management and Research. 2022; 14:1945–1960. doi: 10.2147/CMAR.S287904.

349. Marchese P V, Mollica V, De Biase D, Giunchi F, Tassinari E, Marchetti A, Rosellini M, Nuvola G, Maloberti T, Fiorentino M, Massari F. A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy. Pathology Research and Practice. 2022; 236:153983. doi: 10.1016/j.prp.2022.153983.

350. Iacovelli R, Ciccarese C, Maruzzo M, Atzori F, Galli L, Scagliarini S, Massari F, Verzoni E, Cannella A, Maratta M G, Caserta C, Bimabatti D, Paolieri F, Riccardi F, Bracarda S, De Giorgi U, Basso U, Tortora G, Procopio G. Primary tumor shrinkage and its effect on metastatic disease and outcomes in patients with advanced kidney cancer treated with nivolumab plus ipilimumab or cabozantinib. Clinical Genitourinary Cancer. 2022. doi: 10.1016/j.clgc.2022.06.006.

351. Santoni M, Massari F, Matrana M R, Basso U, De Giorgi U, Aurilio G, Buti S, Incorvaia L, Rizzo M, Martignetti A, Maslov D, Tawagi K, Philon E, Blake Z, Porta C, Battelli N. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer. 2022; 172:191–198. doi: 10.1016/j.ejca.2022.04.035.

352. Rizzo A, Mollica V, Santoni M, Massari F. Clinicopathological features of FGFR3-mutated upper tract urothelial carcinoma: a genomic database analysis. Clinical Genitourinary Cancer. 2022. doi: 10.1016/j.clgc.2022.06.013.

353. Orsatti A, Sirolli M, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Grillini M, Massari F, Mollica V, Bianchi F M, Colecchia M, Fiorentino M, Ricci C. SOX2 and PRAME in the “reprogramming” of seminoma cells. Pathology Research and Practice. 2022; 237:154044. doi: 10.1016/j.prp.2022.154044.

354. Santoni M, Molina-Cerrillo J, Myint Z W, Massari F, Buchler T, Buti S, Matrana M R, De Giorgi U, Rizzo M, Zabalza I O, Galli L, Zucali P A, Aurilio G, Incorvaia L, Bassanelli M, Mammone G, Salfi A, Isella L, Mollica V, Grande E, Porta C, Battelli N. Concomitant use of statins, metformin, or proton pump inhibitors in patients with advanced renal cell carcinoma treated with first-line combination therapies. Target Oncology. 2022. doi: 10.1007/s11523-022-00907-9.

355. Righini M, Mollica V, Rizzo A, La Manna G, Massari F. Renal toxicities in cancer patients receiving immune-checkpoint inhibitors: a meta-analysis. Journal of Clinical Medicine. 2022; 11(15):4373. doi: 10.3390/jcm11154373.

356. Mollica V, Massari F, Andrini E, Rosellini M, Marchetti A, Nuvola G, Tassinari E, Lamberti G, Campana D. Prognostic factors of survival for high-grade neuroendocrine neoplasia of the bladder: a SEER database analysis.Current Oncology. 2022 Aug 18; 29(8): 5846–5854. doi: 10.3390/curroncol29080461.

357. Rizzo A, Mollica V, Marchetti A, Nuvola G, Rosellini M, Tassinari E, Molina-Cerrillo J, Myint ZW, Buchler T, Monteiro FSM, Grande E, Santoni M, Massari F. Adjuvant PD-1 and PD-L1 inhibitors and relapse-free survival in cancer patients: the MOUSEION-04 study. Cancers (Basel). 2022 Aug 26; 14(17): 4142. doi: 10.3390/cancers14174142.

358. Massari F, Mollica V. Personalizing immunotherapy for renal cell carcinoma: how far have we come? Expert Opinion on Biological Therapy. 2022 Sep 9: 1-5. doi: 10.1080/14712598.2022.2122809. Epub ahead of print.

359. Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022 Sep 9. doi: 10.1016/S0140-6736(22)01658-0. Epub ahead of print.

360. Rebuzzi SE et al. The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: the Δ-MEET-URO analysis. Frontiers in Oncology. 2022 Sep 23; 12: 955501. doi: 10.3389/fonc.2022.955501.

361. Raschi E et al. Adrenal insufficiency with anticancer tyrosine kinase inhibitors targeting VEGFR: analysis of the FDA Adverse Event Reporting System. Cancers (Basel). 2022 Sep 22; 14(19): 4610. doi: 10.3390/cancers14194610.

362. Molina-Cerrillo J et al. Epigenetics in advanced renal cell carcinoma: potential new targets. Critical Reviews in Oncology/Hematology. 2022 Oct 15: 103857. doi: 10.1016/j.critrevonc.2022.103857.

363. Man YG et al. The most effective but largely ignored target for prostate cancer early detection and intervention.Journal of Cancer. 2022 Oct 17; 13(13): 3463–3475. doi: 10.7150/jca.72973.

364. Rizzo A, Mollica V, Santoni M, Massari F. Cancer immunotherapy: harnessing the immune system to fight cancer.Journal of Clinical Medicine. 2022 Oct 27; 11(21): 6356. doi: 10.3390/jcm11216356.

365. Viscardi G et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. European Journal of Cancer. 2022 Oct 5; 177: 175–185. doi: 10.1016/j.ejca.2022.09.031.

366. Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology. 2022 Nov 21. doi: 10.1038/s41585-022-00676-0.

367. Ricci C et al. Yolk sac tumor of postpubertal type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1… but choriocarcinoma? Pathology Research and Practice. 2022 Dec 7; 241: 154269. doi: 10.1016/j.prp.2022.154269.

368. Marchese PV et al. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers. Expert Review of Molecular Diagnostics. 2022 Dec 12: 1–12. doi: 10.1080/14737159.2022.2154148.

369. Raschi E, Comito F, Massari F, Gelsomino F. Relatlimab and nivolumab in untreated advanced melanoma: insight into relativity. Immunotherapy. 2023 Jan 11. doi: 10.2217/imt-2022-0172.

370. Santoni M et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology Immunotherapy. 2023 Jan 12. doi: 10.1007/s00262-022-03349-4.

371. Rosellini M et al. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development. 2023.

372. Santoni M et al. Role of clock genes and circadian rhythm in renal cell carcinoma: recent evidence and therapeutic consequences. Cancers (Basel). 2023 Jan 7; 15(2): 408. doi: 10.3390/cancers15020408.

373. Rizzo A et al. Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy. 2023 Jan 25. doi: 10.2217/imt-2022-0023.

374. Rizzo A et al. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunology Immunotherapy. 2023 Jan 25. doi: 10.1007/s00262-023-03366-x.

375. Ricci C et al. H&E and OCT4/CD34 for the assessment of lymphovascular invasion in seminoma and embryonal carcinoma. Pathology Research and Practice. 2023 Jan 24; 242: 154337. doi: 10.1016/j.prp.2023.154337.

376. Marchetti A et al. Prostate cancer and novel pharmacological treatment options — what’s new for 2022? Expert Review of Clinical Pharmacology. 2023 Feb 15. doi: 10.1080/17512433.2023.2181783.

377. Monteiro FSM et al. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): a systematic review and meta-analysis. Clinical Genitourinary Cancer. 2023 Jan 20. doi: 10.1016/j.clgc.2023.01.005.

378. Mollica V, Massari F. Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma. Lancet Oncology.2023 Mar 31. doi: 10.1016/S1470-2045(23)00123-7.

379. Rosellini M et al. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma.Expert Opinion on Drug Safety. 2023 Apr 13. doi: 10.1080/14740338.2023.2203486.

380. Santoni M et al. Clinico-pathological features influencing the prognostic role of body mass index in patients with advanced renal cell carcinoma treated by immuno-oncology combinations (ARON-1). Clinical Genitourinary Cancer.2023 Mar 20. doi: 10.1016/j.clgc.2023.03.006.

381. Tateo V et al. Agnostic approvals in oncology: getting the right drug to the right patient with the right genomics.Pharmaceuticals (Basel). 2023 Apr 19; 16(4): 614. doi: 10.3390/ph16040614.

382. Tateo V et al. Re: WHO Classification of Tumours, 5th Edition, Volume 8: Urinary and Male Genital Tumours.European Urology. 2023 May 10. doi: 10.1016/j.eururo.2023.04.030.

383. Nuvola G et al. Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer. Expert Review of Anticancer Therapy. 2023 Apr 26. doi: 10.1080/14737140.2023.2207827.

384. Melotti S et al. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis. Pathology Research and Practice. 2023 May 18; 247: 154540. doi: 10.1016/j.prp.2023.154540.

385. Maloberti T et al. Multi-gene next-generation sequencing panel for analysis of BRCA1/BRCA2 and homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer. International Journal of Molecular Sciences. 2023 May 18; 24(10): 8940. doi: 10.3390/ijms24108940.

386. Santoni M et al. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunology Immunotherapy. 2023 May 29. doi: 10.1007/s00262-023-03469-5.

387. Antonarakis ES et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial. Journal of Clinical Oncology. 2023 Jun 8. doi: 10.1200/JCO.23.00233.

388. Ricci C et al. FOXA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type. Histopathology.2023 Jun 14. doi: 10.1111/his.14968.

389. Santoni M et al. Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study. Target Oncology. 2023 Jun 27. doi: 10.1007/s11523-023-00978-2.

390. Internò V et al. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study. ESMO Open. 2023 Jul 17; 8(4): 101598. doi: 10.1016/j.esmoop.2023.101598.

391. Santoni M et al. Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk IMDC criteria treated by immune-oncology combinations: differential effectiveness by risk group? European Urology Oncology. 2023 Jul 20. doi: 10.1016/j.euo.2023.07.003.

392. Porta C et al. Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. Minerva Urology and Nephrology. 2023 Aug; 75(4): 460–470. doi: 10.23736/S2724-6051.23.05369-7.

393. Mollica V et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clinical and Experimental Medicine. 2023 Aug 3. doi: 10.1007/s10238-023-01159-1.

394. Fiala O et al. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. Cancer Immunology Immunotherapy. 2023 Sep 7. doi: 10.1007/s00262-023-03518-z.

395. Sridhar SS et al. Avelumab first-line maintenance for advanced urothelial carcinoma: analysis from JAVELIN Bladder 100 by duration of first-line chemotherapy and interval before maintenance. European Urology. 2023 Sep 13. doi: 10.1016/j.eururo.2023.08.001.

396. Nuvola G, Mollica V, Massari F, Suárez C. The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors. Immunotherapy. 2023 Sep 18. doi: 10.2217/imt-2023-0218.

397. Rosellini M et al. Re: Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a phase 3 trial.European Urology. 2023 Sep 28. doi: 10.1016/j.eururo.2023.09.011.

398. Ricci C et al. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT. Virchows Archiv. 2023 Oct 17. doi: 10.1007/s00428-023-03673-9.

399. Conci N et al. How do molecular classifications affect the neoadjuvant treatment of muscle-invasive urothelial carcinoma? Molecular Diagnosis and Therapy. 2023 Oct 24. doi: 10.1007/s40291-023-00679-6.

400. Santoni M et al. Bone targeting agents, but not radiation therapy, improve survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study. Clinical and Experimental Medicine. 2023 Nov 2. doi: 10.1007/s10238-023-01235-6.

401. Monteiro FSM et al. Systemic immune-inflammation index in patients treated with first-line immune combinations for metastatic renal cell carcinoma: insights from the ARON-1 study. Clinical Genitourinary Cancer. 2023

402. Mollica V, Tassinari E, Santoni M, Marchese PV, Giunchi F, Maloberti T, Tateo V, Ricci C, Rosellini M, Marchetti A, Fiorentino M, De Biase D, Massari F. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab. Pathology Research and Practice. 2023 Dec 8; 253:155008. doi: 10.1016/j.prp.2023.155008. Epub ahead of print.

403. Mollica V, Massari F. Adjuvant treatment in renal cell carcinoma: a never-ending story? Lancet. 2023 Dec 14; S0140-6736(23)01672-0. doi: 10.1016/S0140-6736(23)01672-0. Epub ahead of print.

404. Ricci C, Ambrosi F, Grillini A, Massari F, Fiorentino M, Colecchia M, Ulbright TM, Acosta AM. Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation. Virchows Archiv. 2023 Dec 23. doi: 10.1007/s00428-023-03725-0. Epub ahead of print.

405. Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. Journal of Clinical Oncology. 2024 Jan 16: JCO2301569. doi: 10.1200/JCO.23.01569. Epub ahead of print.

406. Santoni M, Takeshita H, Massari F, Bamias A, Cerbone L, Fiala O, Mollica V, Buti S, Santoni A, Bellmunt J. Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nature Reviews Urology. 2024 Jan 24. doi: 10.1038/s41585-024-00858-y. Epub ahead of print.

407. Rosellini M, Mollica V, Marchetti A, Coluccelli S, Giunchi F, Tassinari E, Ricci C, Fiorentino M, Tallini G, De Biase D, Massari F. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: a hypothesis-generating analysis. Pathology Research and Practice. 2024 Jan 17; 254:155142. doi: 10.1016/j.prp.2024.155142. Epub ahead of print.

408. Tassinari E, Rosellini M, Marchetti A, Mollica V, Massari F. What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? Expert Opinion on Drug Metabolism & Toxicology. 2024 Feb 1. doi: 10.1080/17425255.2024.2314059. Epub ahead of print.

409. Conteduca V, Di Tullio P, Allamprese R, Bruno G, Lolli C, Schepisi G, Rosano A, Giordano G, Garofoli M, Chiuri VE, Fratino L, Zanardi E, Galli L, Massari F, Falagario U, Rescigno P, Fornarini G, Sanguedolce F, Santini D, Procopio G, Caffo O, Carrieri G, Landriscina M, De Giorgi U. Initial management approach for localized / locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care. Prostate Cancer and Prostatic Diseases.2024 Feb 12. doi: 10.1038/s41391-024-00800-8. Epub ahead of print.

410. Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, Silini EM, Quaini F, De Filippo M, Brunelli M, Banna GL, Rescigno P, Signori A, Buti S. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.Clinical & Experimental Metastasis. 2024 Feb 16. doi: 10.1007/s10585-024-10266-6. Epub ahead of print.

411. Monteiro FSM, Soares A, Mollica V, Leite CA, Dias Carneiro APC, Rizzo A, Bourlon MT, Sasse AD, Santoni M, Gupta S, Massari F. Efficacy of immune checkpoint inhibitor combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: a systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology. 2024 Mar 7:104321. doi: 10.1016/j.critrevonc.2024.104321. Epub ahead of print.

412. Mollica V, Rosellini M, Brocchi S, Galuppi F, Paccapelo A, Tateo V, Marchetti A, Tassinari E, Mantuano F, Santoni M, Massari F. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development. 2024; 9(1):17–24. doi: 10.1080/23808993.2024.2330422.

413. Iacovelli R, Ciccarese C, Buti S, Zucali PA, Fantinel E, Bimbatti D, Verzoni E, Accettura C, Bonomi L, Buttigliero C, Fornarini G, Pipitone S, Atzori F, Masini C, Massari F, Primi F, Strusi A, Giudice GC, Perrino M, Maruzzo M, Milella M, Giannarelli D, Brunelli M, Procopio G, Tortora G. Avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (TIDE-A Phase II study). European Urology. 2024 Mar 22. doi: 10.1016/j.eururo.2024.02.014. Epub ahead of print.

414. Massari F, Mollica V, Fiala O, De Giorgi U, Kucharz J, Vitale MG, Molina-Cerrillo J, Facchini G, Seront E, Lenci E, Bourlon MT, Carrozza F, Pichler R, Lolli C, Myint ZW, Kanesvaran R, Torniai M, Rescigno P, Gomez de Liaño A, Zakopoulou R, Buti S, Porta C, Grande E, Santoni M. Papillary renal cell carcinoma: outcomes for patients receiving first-line immune-based combinations or tyrosine kinase inhibitors from the ARON-1 study. European Urology Oncology.2024 Apr 3. doi: 10.1016/j.euo.2024.03.011. Epub ahead of print.

415. Mollica V, Massari F, Maruzzo M, Bimbatti D, Claps M, Maiorano BA, Vitale MG, Iacovelli R, Ermacora P, Roviello G, Calabrò F, Caffo O, Vignani F, Grillone F, Pierantoni F, Di Napoli M, Mennitto A, Marchetti A, Mattana A, Cavo A, Bassanelli M, Formisano L, Prati V, Giudice GC, Buti S. Clinical outcomes and prognostic factors in patients with penile carcinoma: a sub-analysis from MEET-URO 23 (I-RARE) registry study. Clinical Genitourinary Cancer. 2024 Mar 18:102074. doi: 10.1016/j.clgc.2024.102074. Epub ahead of print.

416. Massari F et al. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. Cancer Immunology Immunotherapy. 2024 Apr 18; 73(6):106. doi: 10.1007/s00262-024-03682-w.

417. Buti S et al. Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study analysis of heavily pretreated patients. Therapeutic Advances in Urology. 2024 Apr 17; 16:17562872241244574. doi: 10.1177/17562872241244574.

418. Fiala O et al. Real-world impact of upfront cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma treated with first-line immunotherapy combinations or tyrosine kinase inhibitors (ARON-1 retrospective study).Targeted Oncology. 2024 May 5. doi: 10.1007/s11523-024-01065-w.

419. Mollica V et al. A prospective study on early evaluation of response to androgen receptor-targeted agents with ¹¹C-choline, ⁶⁸Ga-PSMA, and ¹⁸F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience.ESMO Open. 2024 May 7; 9(5):103448. doi: 10.1016/j.esmoop.2024.103448.

420. Massari F, Rosellini M, Mollica V. Overall survival with adjuvant pembrolizumab in renal cell carcinoma – the shock of the lightning. Nature Reviews Urology. 2024 May 17. doi: 10.1038/s41585-024-00896-6. Epub ahead of print.

421. Incorvaia L et al. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. Cancer Immunology Immunotherapy. 2024 Jun 4; 73(8):142. doi: 10.1007/s00262-024-03719-0.

422. Rizzo A et al. Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project. Clinical & Experimental Metastasis. 2024 Jun 8. doi: 10.1007/s10585-024-10296-0. Epub ahead of print.

423. Rosellini M et al. Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? Expert Opinion on Biological Therapy. 2024 Jun 19: 1-4. doi: 10.1080/14712598.2024.2369190.

424. Rizzo A et al. Pembrolizumab in patients with advanced urothelial carcinoma with ECOG performance status 2: a real-world study from the ARON-2 project. Targeted Oncology. 2024 Aug 6. doi: 10.1007/s11523-024-01089-2. Epub ahead of print.

425. El Zarif T et al. First-line systemic therapy following adjuvant …immunotherapy in renal cell carcinoma: an international multicenter study. European Urology. 2024 Aug 14; S0302-2838(24)02499-0. doi: 10.1016/j.eururo.2024.07.016. Epub ahead of print.

426. Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators; Massari F. Belzutifan versus everolimus for advanced renal-cell carcinoma. New England Journal of Medicine. 2024 Aug 22; 391(8): 710-721. doi: 10.1056/NEJMoa2313906.

427. Rizzo M et al. Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study. Scientific Reports. 2024 Aug 27; 14(1): 19802. doi: 10.1038/s41598-024-70182-3.

428. Ciccarese C et al. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study). International Journal of Cancer. 2024 Sep 7. doi: 10.1002/ijc.35141. Epub ahead of print.

429. Di Sciascio L et al. Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel. Virchows Archiv. 2024 Sep 11. doi: 10.1007/s00428-024-03911-8. Epub ahead of print.

430. Santini D et al. Real-world primary resistance to first-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1). Targeted Oncology. 2024 Sep 17. doi: 10.1007/s11523-024-01096-3. Epub ahead of print.

431. Fiala O et al. Enfortumab vedotin following platinum chemotherapy and avelumab maintenance in patients with metastatic urothelial carcinoma: data from the ARON-2 EV study. Targeted Oncology. 2024 Oct 1. doi: 10.1007/s11523-024-01099-0.

432. De Giglio A et al. Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy. Cancer Immunology Immunotherapy. 2024 Oct 3; 73(12): 246. doi: 10.1007/s00262-024-03836-w.

433. Compagno S et al. Novel immune checkpoint inhibitor targets in advanced or metastatic renal cell carcinoma: state of the art and future perspectives. Journal of Clinical Medicine. 2024 Sep 26; 13(19): 5738. doi: 10.3390/jcm13195738.

434. Vitale E et al. Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis. Scientific Reports. 2024 Nov 16; 14(1): 28309. doi: 10.1038/s41598-024-71746-z.

435. Santoni M et al. Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study. European Urology Oncology. 2024 Nov 28; S2588-9311(24)00253-0. doi: 10.1016/j.euo.2024.11.005.

436. Rizzo A, Monteiro FSM, Mollica V, Soares A, Brunetti O, Vitale E, Sciacovelli AM, Massari F, Santoni M. Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis. Clinical & Experimental Metastasis. 2024 Dec 16; 42(1): 3. doi: 10.1007/s10585-024-10322-1.

437. Tassinari E, Danielli L, Marchetti A, Rosellini M, Ricci C, Piazza P, Mottaran A, Schiavina R, Santoni M, Mollica V, Massari F. State of the art of adjuvant immunotherapy in urothelial cancer: new developments and upcoming changes.Human Vaccines & Immunotherapeutics. 2025 Dec; 21(1): 2440165. doi: 10.1080/21645515.2024.2440165.

438. Rizzo A, Monteiro FSM, Mollica V, Brunetti O, Vitale E, Sciacovelli AM, Soares A, Massari F, Santoni M. Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study. Clinical & Experimental Metastasis. 2024 Dec 30; 42(1): 9. doi: 10.1007/s10585-024-10327-w.

439. Roviello G, Molina-Cerrillo J, Massari F, Cerbone L, Fiala O, Fornarini G, Monteiro FSM, Cattrini C, Landmesser J, Messina C, Zgura A, Rebuzzi SE, Soares A, Carrozza F, Ansari J, Grillone F, Küronya Z, Incorvaia L, Bhuva D, Ortega C, Nasso C, Kanesvaran R, Zampiva I, Porta C, Buti S, Santoni M. First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study. Cancer Immunology Immunotherapy. 2025 Jan 3; 74(2): 65. doi: 10.1007/s00262-024-03897-x.

440. Santoni M, Mollica V, Rizzo A, Massari F. Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma. Cancer Treatment Reviews. 2025 Jan 6; 133: 102881. doi: 10.1016/j.ctrv.2025.102881.

441. Corianò M et al. Role of Hb-to-RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations. Immunotherapy. 2025 Jan 20: 1-11. doi: 10.1080/1750743X.2025.2452145.

442. Giudice GC et al. Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review.Expert Review of Anticancer Therapy. 2025 Feb 10. doi: 10.1080/14737140.2025.2464929.

443. Marchetti A et al. Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? Expert Review of Molecular Diagnostics. 2025 Feb 13. doi: 10.1080/14737159.2025.2467962.

444. Fiala O et al. Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2 EV study. Clinical & Experimental Metastasis. 2025 Feb 20; 42(2): 18. doi: 10.1007/s10585-025-10335-4.

445. Rizzo M et al. Real-life impact of enfortumab vedotin or chemotherapy in the sequential treatment of advanced urothelial carcinoma: the ARON-2 retrospective experience. Cancer Medicine. 2025 Feb; 14(4): e70479. doi: 10.1002/cam4.70479.

446. Santoni M, Rizzo A, Massari F. Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in urothelial carcinoma. Expert Opinion on Investigational Drugs. 2025 Feb 26. doi: 10.1080/13543784.2025.2473695.

447. Rosellini M et al. The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? Expert Review of Molecular Diagnostics. 2025 Mar 11. doi: 10.1080/14737159.2025.2478996.

448. Incorvaia L et al. Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.Scientific Reports. 2025 Mar 14; 15(1): 8815. doi: 10.1038/s41598-025-93094-2.

449. Danielli L et al. Current androgen-receptor antagonists under investigation for resistant prostate cancer: progress and challenges. Expert Review of Anticancer Therapy. 2025 Mar 16. doi: 10.1080/14737140.2025.2481141.

450. Vitale E et al. Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis. Immunotherapy. 2025 Mar 25: 1-13. doi: 10.1080/1750743X.2025.2483656.

451. Rosellini M et al. Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: a single-center experience. Pathology Research and Practice. 2025 Apr 9; 270: 155964.

452. Porta C et al. Pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study. Cancer Immunology Immunotherapy. 2025 May 9; 74(7): 196. doi: 10.1007/s00262-025-04019-x.

453. Santoni M et al. Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in metastatic renal cell carcinoma: a real-world comparison (ARON-1). Cancer Immunology Immunotherapy. 2025 May 27; 74(7): 225. doi: 10.1007/s00262-025-04043-x.

454. Vitale E et al. Normal weight, overweight and obesity conditions associated with prostate neoplasm stages: a systematic review and meta-analysis. Biomedicines. 2025 May 13; 13(5): 1182. doi: 10.3390/biomedicines13051182.

455. Vescovo M et al. Storage time and DNA quality determine BRCA1/2 sequencing success in prostate cancer: a multicentre analysis with therapeutic implications. Cancers (Basel). 2025 May 20; 17(10): 1705. doi: 10.3390/cancers17101705.

456. Bruno G et al. Real-world outcomes and molecular profiling for patients with metastatic castration-resistant prostate cancer with lung metastases: a long-term multicenter experience. European Urology Oncology. 2025 Jun 2. doi: 10.1016/j.euo.2025.05.002.

457. Santoni M, Massari F. Re: Using deep learning to differentiate among histology renal tumor types in computed tomography scans. European Urology. 2025 Jun 7. doi: 10.1016/j.eururo.2025.05.028.

458. Mottaran A et al. Feasibility and setting of single-docking Hugo RAS robot-assisted nephroureterectomy: first European experience. Minerva Urology & Nephrology. 2025 Jun; 77(3): 396-400. doi: 10.23736/S2724-6051.25.06209-3.

459. Rizzo M et al. Geographical differences in the management and outcomes of patients with advanced urothelial carcinoma treated with pembrolizumab after progression on platinum-based chemotherapy: results from ARON-2. JCO Global Oncology. 2025 Jul; 11:e2400564. doi: 10.1200/GO-24-00564.

460. Massari F et al. Immune-based combinations in intermediate/poor-risk non-clear-cell renal cell carcinoma: results from the ARON-1 study. European Urology Focus. 2025 Jul 29. doi: 10.1016/j.euf.2025.05.020.

461. Bourlon MT et al. Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study. Frontiers in Oncology. 2025 Jul 25; 15: 1605282. doi: 10.3389/fonc.2025.1605282.

462. Massari F et al. Re: First-line therapy for advanced non-clear-cell renal cell carcinoma – a systematic review and meta-analysis. European Urology. 2025 Aug 12. doi: 10.1016/j.eururo.2025.07.022.

463. Ricci C et al. The absence of FOXA2 and HNF1β expression in vasculogenic mesenchymal lesions of germ cell origin suggests an evolutionary pathway similar to that of sarcomatoid yolk sac tumor. Virchows Archiv. 2025 Aug 18. doi: 10.1007/s00428-025-04223-1.

464. Aguzzi C et al. mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α). Biochemical and Biophysical Reports. 2025 Aug 7; 43: 102162. doi: 10.1016/j.bbrep.2025.102162.

465. Marchetti A et al. The prognostic role of ⁶⁸Ga-PSMA-PET/CT in metastatic hormone-sensitive prostate cancer: a preliminary analysis. Clinical Genitourinary Cancer. 2025 Jul 29. doi: 10.1016/j.clgc.2025.102406.

466. Rizzo A et al. Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world validation from ARON-2 dataset. Clinical & Experimental Metastasis. 2025 Sep 6; 42(5): 52. doi: 10.1007/s10585-025-10374-x.

467. Ricci C et al. Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study. Virchows Archiv. 2025 Sep 11. doi: 10.1007/s00428-025-04243-x.

468. Melotti S et al. Immunohistochemical expression of EZH2 in germ cell tumors of the testis: new insights into the genesis and epigenetic reprogramming of these tumors. American Journal of Clinical Pathology. 2025 Sep 17. doi: 10.1093/ajcp/aqaf098.

469. Mandel P et al. 177Lu-PSMA versus cabazitaxel in patients with castration-resistant prostate cancer: real-world efficacy and safety data from the ARON-3 study. European Journal of Cancer. 2025 Sep 12; 229: 115789. doi: 10.1016/j.ejca.2025.115789.

Book Chapters

1. Massari F. Translator and curator of the Italian version of “The Merck Manual” – Springer Editor, 18th Edition, 2006.

2. Massari F. “ECM e Oncologia”, in Professione oncologo. Formazione e percorsi di crescita professionale continua, Il Pensiero Scientifico Editore, November 2010, p. 187 ff.

3. Massari F. “Cenni di terapia adiuvante”, in Camici invisibili, edited by B. Buralli & D. Amoroso, Franco Angeli Editore, 2011, p. 97 ff.

4. Bria E, Massari F, Pilotto S, Maines F, Tortora G. “Neoplasie a sede primitiva ignota”, in La Medicina Oncologica, EDRA, September 2013 Edition, Chapter 18, pp. 691–707.

5. Massari F. Translator and curator of the Italian version of “The Merck Manual” – Springer Editor, 19th Edition, 2011. ISBN: 978-88-470-5497-4.

6. Di Lorenzo G, Palmieri G, Bianco AR, Massari F. “Tumori Urologici”, in Core Curriculum Oncologia Clinica, McGraw-Hill Education, 2nd Edition, September 2015, Chapter 14, pp. 227–254. ISBN: 978-88-386-3984-5.

7. Matano E, Massari F, Bria E. “Emergenze in Oncologia”, in Core Curriculum Oncologia Clinica, McGraw-Hill Education, 2nd Edition, September 2015, Chapter 21, pp. 227–254. ISBN: 978-88-386-3984-5.

8. Santoni M, Massari F. “mTOR Pathway in Renal Cell Carcinoma”, in Molecules to Medicine with mTOR, Academic Press, 2016, Chapter 25, pp. 417–428. doi: 10.1016/B978-0-12-802733-2.00026-8.

Francesco Massari

Present Title & Affiliation

Education & Training

Professional Positions and Employment

Hospital Appointments

Institutional Leadership Activities

Institutional Administrative Activities

Professional Organizations and Society Memberships

Languages

Additional Skills and Interests

Abstract:

Full papers:

Book Chapters

OncoDaily

Oncology

cancer

fight against cancer

Global fight against cancer

Breast Cancer

cancer care

ASCO

Lung cancer

Cancer research

ESMO

MD Anderson Cancer Center

NSCLC

cancer awareness

immunotherapy

cancer treatment

Headlines

Research

ASCO24

colorectal cancer

Childhood Cancer

prostate cancer

clinical trials

AACR

FDA

Dana-Farber Cancer Institute

UICC

European Cancer Organisation

American Cancer Society

NCI

National Cancer Institute

SIOP

chemotherapy

Vivek Subbiah

healthcare

American Society of Clinical Oncology

ASCO25

AI

Paolo Tarantino

Robert Orlowski

IASLC

radiation oncology

Myeloma Paper of the Day

WHO

Myeloma

Memorial Sloan Kettering Cancer Center

multiple myeloma

Zainab Shinkafi-Bagudu

cervical cancer

Pancreatic Cancer

European School of Oncology

Sitemap